WO2022037514A1 - 药物和野生型穿膜肽衍生物的组合物 - Google Patents

药物和野生型穿膜肽衍生物的组合物 Download PDF

Info

Publication number
WO2022037514A1
WO2022037514A1 PCT/CN2021/112687 CN2021112687W WO2022037514A1 WO 2022037514 A1 WO2022037514 A1 WO 2022037514A1 CN 2021112687 W CN2021112687 W CN 2021112687W WO 2022037514 A1 WO2022037514 A1 WO 2022037514A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
ranibizumab
drug
wild
penetratin
Prior art date
Application number
PCT/CN2021/112687
Other languages
English (en)
French (fr)
Inventor
魏刚
江宽
李德晃
王雁峰
Original Assignee
奥朗生物医药有限公司
复旦大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 奥朗生物医药有限公司, 复旦大学 filed Critical 奥朗生物医药有限公司
Priority to US18/021,868 priority Critical patent/US20230357334A1/en
Priority to CA3192067A priority patent/CA3192067A1/en
Priority to JP2023512007A priority patent/JP2023539460A/ja
Priority to EP21857609.8A priority patent/EP4197558A1/en
Publication of WO2022037514A1 publication Critical patent/WO2022037514A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Definitions

  • the invention belongs to the field of pharmaceutical preparations, relates to a composition for treating eye diseases, and more particularly relates to a composition comprising a derivative of the wild-type penetratin and a drug with positive charge under physiological pH conditions.
  • CPPs Cell-penetrating peptides
  • the derivatives of wild-type penetratin retain the positive charge of wild-type penetratin under physiological pH conditions, it is believed in the prior art that the derivatives of wild-type penetratin interact with physiological pH conditions through electrostatic interaction.
  • the negatively charged drug binds and enables intraocular delivery.
  • the derivatives of wild-type penetratin can self-assemble with biomacromolecular drugs such as negatively charged genes, polypeptides and proteins under physiological pH conditions to form nanocomplexes through electrostatic interactions, or in the presence of polymers It self-assembles with biomacromolecular drugs such as negatively charged genes, polypeptides and proteins under physiological pH conditions to form nanocomplexes, and realizes the intraocular delivery of the above-mentioned biomacromolecular drugs. See, for example, Chinese patent application CN108976288(A).
  • the purpose of the present invention is to provide a combination of artificially engineered cell-penetrating peptides (CPPs) and drugs.
  • CPPs cell-penetrating peptides
  • the present invention provides a composition for treating eye diseases, the composition comprising:
  • a derivative of the wild-type penetrating peptide penetratin has the following amino acid sequence:
  • X 1 , X 2 and X 3 represent hydrophobic amino acids, selected from the naturally derived amino acids alanine (A), valine (V), leucine (L), isoleucine Amino acid (isoleucine, I), proline (proline, P), phenylalanine (phenylalanine, F), tryptophan (tryptophan, W), methionine (methionine, M) and non-natural sources
  • the amino acids ⁇ -aminobutyric acid, ⁇ -aminopentanoic acid, ⁇ -aminohexanoic acid, ⁇ -aminoheptanoic acid, and their combination.
  • composition for treating eye diseases according to the present invention preferably, the composition is a solution or a suspension.
  • X 1 , X 2 and X 3 represent hydrophobic amino acids, and at least two of X 1 , X 2 and X 3 are selected from the amino acid alanine of natural origin Acid (alanine, A), valine (valine, V), leucine (leucine, L), isoleucine (I), proline (proline, P), phenylalanine (phenylalanine) , F), tryptophan (W), methionine (M) and unnatural amino acids ⁇ -aminobutyric acid ( ⁇ -aminobutyric acid), ⁇ -aminopentanoic acid ( ⁇ -aminopentanoic acid) ), ⁇ -aminohexanoic acid, ⁇ -aminoheptanoic acid, and combinations thereof.
  • X 1 , X 2 or X 3 is tryptophan (W).
  • composition for treating eye diseases according to the present invention preferably at least two of X 1 , X 2 or X 3 are tryptophan (W).
  • the amino acid sequence of the derivative of the wild-type penetratin is:
  • the amino acid sequence of the derivative of the wild-type penetratin is:
  • the drug is a polypeptide or protein drug.
  • the drug is selected from one or more of the following: Nanobody, Ranibizumab, Aflibercept ), Ocriplasmin, Bevacizumab, Adalimumab, Atezolizumab, Belimumab, Cetuximab (Cetuximab), Dalotuzumab, Denosumab, Elotuzumab, Infliximab, Ipilimumab, Ichi Ixekizumab, Natalizumab, NISTmab, Nivolumab, Obinutuzumab, Ofatumumab , Palivizumab, Pembrolizumab, Pertuzumab, Ramucirumab, Rituximab, Trastuzumab (Trastuzumab) and Endostatin.
  • the drug is selected from one or more of the following: Nanobody, ranibizumab, aflibercept, octoplasmin, bevac monoclonal antibody and cetuximab.
  • the drug is selected from one or more of the following: ranibizumab, aflibercept and bevacizumab.
  • the nanobody is selected from one or more of the following: Caplacizumab, Ozoralizumab, and Vobarilizumab.
  • the ratio of the derivative of the wild-type penetratin to the drug is 0.1:1-50:1 in molar ratio.
  • the ratio of the derivative of the wild-type penetratin to the drug is 0.5:1-35:1 in molar ratio.
  • the ratio of the derivative of the wild-type penetratin to the drug is 1:1-20:1 in molar ratio.
  • the most preferred ratio of the derivative of the wild-type penetratin to the drug is 3:1-15:1 in molar ratio.
  • the present invention also provides a method of treating an ocular disorder in a subject in need thereof, the method comprising administering a therapeutically effective amount of a composition for treating an ocular disorder according to the present invention.
  • the method of the present invention preferably comprises administering a therapeutically effective amount of the composition according to the present invention to a patient by eye drop.
  • the present invention also provides the use of the composition in preparing a medicament for treating eye diseases.
  • Figure 2 Flow diagram (left) and mean fluorescence intensity comparison (right) of 28WP promoting Nanobody uptake in human corneal epithelial cells.
  • Figure 3 Uptake of 89WP/Nanobody compositions at different ratios in human retinal pigment epithelial cells.
  • Figure 4 29WP promotes the uptake of octoplasmin in human retinal pigment epithelial cells under different molar ratios.
  • Figure 5 289WP promotes the uptake of cetuximab in human corneal epithelial cells under different molar ratios.
  • Figure 6 Quantitative assessment of cellular uptake of peptide/ranibizumab compositions under different molar ratios.
  • Figure 7 Quantitative evaluation of cellular uptake of peptide/ranibizumab compositions under different molar ratios.
  • Figure 8 Quantitative assessment of cellular uptake of polypeptide/ranibizumab compositions prepared with different polypeptides.
  • Figure 9 Synchronous uptake behavior of polypeptide/ranibizumab compositions in human corneal epithelial cells.
  • Figure 10 Synchronous uptake behavior of peptide/ranibizumab compositions in human retinal pigment epithelial cells.
  • Figure 11 Mechanism of cellular uptake of peptide/ranibizumab composition eye drops.
  • Figure 12 Ranibizumab concentrations in various tissues (plasma, aqueous humor, vitreous body, retina) in rabbits after eye-drop administration of the polypeptide/ranibizumab composition for 1 h.
  • Figure 13 Changes in the concentration distribution of ranibizumab in rabbits after eye-drop administration of the peptide/ranibizumab composition.
  • Figure 14 Concentration distribution of aflibercept in rabbits after eye-drop administration of the polypeptide/aflibercept composition.
  • the present invention uses an artificially modified penetrating peptide as an ocular absorption enhancer, which can be administered by eye drops through a non-traumatic route, and will be positively charged under physiological pH conditions through non-covalent connection.
  • the charged drug is delivered into the eye.
  • the penetrating peptide is a positively charged short peptide under physiological pH conditions, and the drug is a positively charged drug under physiological pH conditions.
  • Applicants have unexpectedly found that the combination of a positively charged penetrating peptide at the physiological pH condition and a positively charged drug at the physiological pH condition can significantly promote cellular uptake.
  • the composition results in a significant increase in cellular uptake compared to the use of only the positively charged drug at the physiological pH.
  • the present invention provides a composition for treating ocular diseases, the composition comprising: (i) a positively charged drug under physiological pH conditions, and (ii) a derivative of the wild-type penetrating peptide penetratin.
  • the derivative of the wild-type penetrating peptide penetratin is based on the natural source penetrating peptide penetratin, a series of polypeptide derivatives with good penetrability to eye tissue and high biosafety are designed and prepared by adopting the method of amino acid mutation, Drugs that are positively charged under physiological pH conditions mixed with them can be delivered into the eye by atraumatic routes.
  • composition of the present invention can mediate the positively charged drug under the physiological pH condition to efficiently pass through the absorption barrier of the eye, promote the drug to enter the eye and reach the posterior segment of the eye, thereby improving the positive charge under the physiological pH condition. Ocular bioavailability of charged drugs.
  • amino acid sequence of the wild-type polypeptide penetratin is as follows:
  • the penetratin derivative of the present invention uses amino acid mutation technology to introduce hydrophobic amino acids into its molecule, thereby enhancing the eye tissue penetration of the obtained penetratin derivative ability.
  • the present invention maintains the original basic amino acids arginine (arginine, R), lysine (lysine, K) and the original hydrophobic amino acid isoleucine (
  • the sequences of isoleucine (I), phenylalanine (F), tryptophan (W), and methionine (M) remain unchanged, and are replaced with hydrophobic amino acids by solid-phase peptide synthesis technology.
  • the hydrophilic amino acids glutamine (Q) and asparagine (N) in the penetratin molecule are used to obtain a series of polypeptide derivatives.
  • the penetratin derivatives are characterized by substitution of different hydrophilic amino acid (glutamine and asparagine) sites of wild type penetratin with different hydrophobic amino acids.
  • the hydrophobic amino acid is selected from the naturally derived amino acids alanine (A), valine (V), leucine (L), isoleucine (I), proline Acid (proline, P), phenylalanine (phenylalanine, F), tryptophan (tryptophan, W), methionine (methionine, M) and non-natural source amino acid ⁇ -aminobutyric acid ( ⁇ -aminobutyric acid) acid), ⁇ -aminopentanoic acid, ⁇ -aminohexanoic acid, ⁇ -aminoheptanoic acid, and the like, and combinations thereof.
  • amino acid sequences of polypeptide derivatives obtained by structural modification on the basis of wild-type penetratin are shown in Table 1, wherein the mutated amino acids are marked with underlines. No examples of mutations of unnatural amino acids are given in this table, only representative examples of combined mutations of different hydrophobic amino acids are given.
  • penetratin derivatives to ocular tissue is related to its hydrophobicity (lipophilicity), and the stronger the hydrophobicity (lipophilicity), the stronger the penetration ability of penetratin derivatives to ocular tissue. Therefore, penetratin derivatives prepared with other hydrophobic amino acids will also obtain enhanced ocular absorption promoting effect.
  • the penetratin derivative described in the present invention is easy to degrade and thus has better biological safety.
  • polypeptide absorption enhancers are easy to be modified and modified to achieve different application goals, and the penetratin derivative of the present invention has stronger ocular absorption promotion ability than wild-type penetratin of natural origin.
  • isoelectric point refers to the pH value at which the net charge of a molecule such as a protein or polypeptide is zero. See, for example, literature: Kentaro Tomii. Protein Properties. Encyclopedia of Bioinformatics and Computational Biology. 2019, 2: 28-33. (doi: 10.1016/B978-0-12-809633-8.20266-5). Since the charge of the zwitterion varies with the pH value of the solution, when the positive and negative charges of the zwitterion are equal, the pH value of the solution is its isoelectric point.
  • drugs with positive charges under physiological pH conditions that is, drugs with an isoelectric point higher than 7.45, such as polypeptide or protein drugs.
  • physiological pH conditions refer to: under physiological conditions, the pH range of the human body is between 7.35 and 7.45, with an average value of 7.40.
  • the pH of blood in humans is maintained within a narrow range of 7.4 ⁇ 0.03.
  • composition of the present invention can be obtained by:
  • the derivative of the wild-type penetrating peptide penetratin is prepared by physical mixing with a positively charged polypeptide or protein drug under physiological pH conditions.
  • the inventors compared the effects of the composition of the present invention in promoting cellular uptake in vitro through cell uptake experiments.
  • the double mutation (28WP, 29WP, 89WP) and triple mutation (289WP) derivatives had better effect in promoting absorption.
  • the positively charged protein drugs under physiological pH conditions include ranibizumab, isoelectric point 8.8; bevacizumab, isoelectric point 8.8; and aflibercept, isoelectric point 8.2.
  • the composition has the best absorption promoting effect especially when the molar ratio is between 5:1 and 35:1.
  • Nanobodies are a novel and unique class of antigen-binding fragments derived from heavy chain antibodies naturally present in alpaca serum. Nanobodies are recombinant, single-domain variable fragments derived from alpaca heavy chain antibodies that selectively bind to specific antigens. See for example the literature: I, Muyldermans S. The Therapeutic Potential of Nanobodies. BioDrugs. 2020, 34: 11-26; Rubel Chakravarty, Shreya Goel, Weibo Cai. Nanobody: The “Magic Bullet” for Molecular Imaging? Theranostics 2014;4(4):386-398.
  • Common nanobodies include: Caplacizumab (generic name ALX 0681 or ALX-0081, trade name Cablivi), molecular weight 28kDa, isoelectric point 9.2; Ozoralizumab (generic name ATN-103), molecular weight 38kDa, isoelectric point 8.8; Vobarilizumab (generic name ATN-103) Name ALX-0061), molecular weight 26kDa, isoelectric point 8.7.
  • Nanobodies can be delivered into the eye (including the cornea of the anterior segment of the eye and the retina of the posterior segment of the eye) by administering the composition by eye drop.
  • the Nanobody alone almost no absorption occurred.
  • the cellular uptake of a composition comprising 89WP and a nanobody with a molar ratio of the two ranging from 5:1 to 50:1 was compared with a drug containing only a nanobody, 89WP, a derivative of penetratin without the wild-type penetrating peptide.
  • the best effect of promoting uptake was obtained when the molar ratio of 89WP to Nanobody was 10:1-15:1.
  • the ratio of 89WP to Nanobody was 5:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, respectively. 1, 40:1, 45:1 and 50:1 compositions were compared.
  • the results showed that the two sets of compositions with 89WP:Nanobody ratios of 10:1 and 15:1 obtained the most cellular uptake.
  • ranibizumab can be delivered to the eye (including the retina in the posterior segment of the eye) by the composition in rabbits and vitreous). The effect is significantly better than the control R8.
  • R8 is the abbreviation of 8-polyarginine (arginine, R), which is a classic synthetic penetrating peptide. It has been reported that ranibizumab and bevacizumab were delivered to the mouse eye by eye drop administration using the homolog of R8, 6-polyarginine (R6). See for example: Invest Ophthalmol Vis Sci. 2017;58(5):2578-2590.doi:10.1167/iovs.16-20072.. There are also reports in the literature that R8 has a better absorption promotion effect than R6. See, for example: J Control Release. 2007;118(2):177-84.doi:10.1016/j.jconrel.2006.12.022.
  • the inventors use R8 as a control to prove that the effect of the present invention is better than that of R8, thereby proving that the present invention obtains a technical effect better than that of R6 reported in the literature. No absorption will occur if 89WP is not added.
  • the derivatives of wild-type penetratin (R6 (6-polyarginine), wild-type Penetratin, 2WP, 8WP, 9WP, 28WP, 29WP, 89WP, 289WP) and Raizhu were screened in vitro by cell uptake assay.
  • the composition of monoclonal antibody, the molar ratio was set to 10:1, and 2 different cells were selected, among which 29WP and 289WP had the best effect, and the derivative without wild-type penetratin only contained ranibizumab. Cellular uptake was significantly increased compared to the composition.
  • the composition of 89WP and ranibizumab was screened in vitro by cell uptake assay. Three different cells were selected, and the molar ratio of the two varied from 5:1 to 18:1. Cellular uptake was significantly increased compared to the composition. Compared with the composition containing the peptide R8 and ranibizumab, which are reported to have absorption-promoting effects in the literature (the ratio of R8:ranibizumab is between 5:1-30:1, higher than the ratio of 89WP:ranibizumab) , the cellular uptake was significantly increased. As shown in Figures 4 and 5, cellular uptake was increased 2.2-6.7-fold.
  • composition of 289WP and ranibizumab was screened in vitro by cell uptake assay, and two different cells were selected. It was confirmed that after 289WP and ranibizumab formed a composition (molar ratio of 10:1), the two were simultaneously taken up by cells .
  • the composition of 29WP and 289WP and ranibizumab was screened in vitro by cell uptake assay, and 29WP and 289WP were used to form complexes with ranibizumab (molar ratio 10:1), respectively, and it was confirmed in rabbits by eye drop administration
  • Ranibizumab can be delivered into the eye (including the aqueous humor in the anterior segment of the eye, and the retina and vitreous in the posterior segment of the eye). Without the addition of a derivative of the wild-type penetratin peptide, ranibizumab was hardly absorbed.
  • the inventors unexpectedly found that derivatives of wild-type penetratin can interact with ranibizumab that is positively charged under physiological pH conditions, and derivatives of wild-type penetratin Ability to bring ranibizumab into the eye.
  • the combination of 289WP and aflibercept was screened in vitro using cellular uptake assays. Among them, using 289WP and aflibercept to form a composition (molar ratio of 10:1), it was confirmed in rabbits that aflibercept could be delivered to the eye (including the aqueous humor in the anterior segment of the eye, the back of the eye) by eye drop administration. segment of retina and vitreous). Without the addition of a derivative of the wild-type penetratin, aflibercept is hardly absorbed.
  • the penetratin derivative in the composition of the present invention retains the positive charge characteristic of wild-type penetratin under physiological pH conditions, and forms a composition in a non-covalent manner with a drug that is positively charged under physiological pH conditions, which is unexpected. Better intraocular delivery of the above-mentioned drugs is achieved.
  • the present invention demonstrates that administration by eye drops can deliver drugs such as Nanobodies into the eye, including the delivery of drugs such as Nanobodies to the cornea of the anterior segment of the eye and the retina in the posterior segment of the eye.
  • administration by eye drops can deliver drugs such as ranibizumab and aflibercept into the eye, including drugs such as ranibizumab and aflibercept are delivered to the cornea of the anterior segment of the eye and the retina of the posterior segment of the eye. This delivery effect could not be obtained by administering the drug alone without including the derivative of the wild-type penetratin.
  • the peptides were synthesized by solid-phase synthesis technology, and the peptide sequences are shown in Table 3.
  • the crude product after lyophilization was purified using the preparation liquid.
  • the preparation column was a Waters XBridge TM BEH130 Prep C18 column (19 ⁇ 250 mm, 10 ⁇ m). After lyophilization, the subsequent purity and molecular weight characterizations were performed.
  • Chromatographic column YMC-Pack ODS-A column (4.6 ⁇ 150mm, 5 ⁇ m);
  • phase A is pure water (containing 0.1% TFA)
  • phase B is acetonitrile (containing 0.1% TFA)
  • the mobile phase method of the derivative of wild-type penetratin is 5-65% B, 30min
  • the method of polypeptide R6 is 2-32%B, 30min;
  • the molecular weight of the polypeptide was investigated by electrospray ionization mass spectrometry (ESI-MS), and the detection conditions were as follows:
  • Drying gas temperature and flow rate 350°C, 12L/min.
  • the purity and molecular weight of the peptides are shown in Table 4, and the specific spectral information is shown in Figure 1.
  • the liquid-phase purity of all peptides was above 95%, and the molecular weight was correct, which could be used in subsequent experiments.
  • Example 2 Polypeptide promotes uptake of Nanobodies by ocular cells
  • Polypeptide 28WP and Cy5-labeled Nanobody were dissolved in phosphate buffer solution (PBS, concentration 10 mM, pH 7.4), respectively.
  • PBS phosphate buffer solution
  • the 28WP solution and Cy5-labeled Nanobody solution were mixed in a molar ratio of 5:1, and placed at room temperature for 24 hours.
  • a 28WP and Nanobody composition was obtained.
  • HCECs human corneal epithelial cells
  • ARPE-19 cells were plated in 24-well plates and cultured for more than 24 hours. The culture medium was discarded, and 200 ⁇ L of the drug solution and 300 ⁇ L of serum-free culture medium were added to each well. After incubation for 2 h, the drug solution was discarded, and the cells were washed three times with PBS. The cells were digested and resuspended in PBS, and the Cy5 fluorescence signal (Ex 645nm) was detected by flow cytometry. , Em 665nm).
  • Figure 3 shows the uptake of 89WP/Nanobody compositions at different ratios in ARPE-19 cells.
  • the molar ratio of 89WP to Nanobody is 5:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, respectively .
  • the results show that within this ratio range, 89WP can significantly promote the cellular uptake of Nanobodies, and the uptake effect is better in the molar ratio range of 10:1-30:1. Therefore, the preferred molar ratio of 89WP to Nanobody is in the range of 5:1 to 35:1, more preferably 10:1 to 30:1.
  • Polypeptide 29WP and Cy5-labeled Ocriplasmin (Ocriplasmin, isoelectric point 7.7, molecular weight 27kD) were dissolved in citric acid buffer solution (concentration 0.53mg/mL), respectively, and the 29WP solution was mixed with Cy5-labeled Ocriplasmin.
  • the solutions were mixed in molar ratios of 0.1:1, 0.3:1, 0.5:1, 0.7:1, 0.9:1 and 1:1, and were placed at room temperature for 24 hours to obtain a composition of 29WP and Aoke plasmin.
  • Polypeptide 289WP and Cy5-labeled cetuximab (Cetuximab, isoelectric point 8.8, molecular weight 152kD) were dissolved in phosphate buffer solution (PBS, concentration 10 mM, pH 7.4), respectively, and the 289WP solution was mixed with Cy5-labeled cetuximab.
  • the monoclonal antibody solution was mixed in a molar ratio of 0.5:1, 0.7:1, 1:1, 3:1, 5:1, 7:1 and 10:1, and placed at room temperature for 24 hours to obtain the combination of 289WP and cetuximab thing.
  • HCEC human corneal epithelial cells
  • composition of polypeptide 289WP and cetuximab can increase the uptake of cetuximab in human corneal epithelial cells by 12 to 32 times under the condition of molar ratio of 0.5:1 to 10:1 .
  • ranibizumab was fluorescently labeled. Take a certain amount of ranibizumab injection, dialyze it in pure water at 4°C for 3 days to desalt (molecular weight cut-off 10kD), take 5 mg after lyophilization and redissolve it in 100 mM Na 2 CO 3 solution, add 0.12 mg of fluorescent labeling reagent Sulfo-Cy5- NHS, stirred overnight at 4°C, the system was dialyzed in pure water at 4°C for 3 days and then freeze-dried to obtain fluorescently labeled ranibizumab (Cy5-Rani).
  • the polypeptide/ranibizumab composition was then prepared. Weigh an appropriate amount of polypeptide, dissolve it with a certain volume of commercially available ranibizumab injection, add an equal volume of commercially available ranibizumab injection solvent, and store at 4°C for later use.
  • the results showed that the peptide-mediated cellular uptake of ranibizumab showed an upward trend at the molar ratio of 1:1 to 10:1.
  • the molar ratio of 89WP to ranibizumab was further optimized. Under the conditions of 5:1 to 18:1, the uptake of polypeptide 89WP-mediated antibody in three cells increased by 2.2-6.7 times compared with free antibody. (p ⁇ 0.001); with the increase in the amount of polypeptide, the uptake of antibody cells showed an overall upward trend. In HCEC cells, there was no significant difference in the uptake of antibody cells under the condition of molar ratio of 10:1 and molar ratio of 7:1 and 12:1.
  • Figure 8 is a quantitative evaluation of the cellular uptake of ranibizumab mediated by different polypeptides. Among them, mix 10 ⁇ M of different polypeptides with 1 ⁇ M Cy5-Rani, and incubate at 4 °C for 24 h to obtain a composition solution. The composition solution was incubated with different cells at 37 °C for 2 h and detected, or the composition solution was stored at 4 °C for 7 days and then mixed with cells After incubation, the mean fluorescence intensity value of cells (Ex 638nm/Em 660nm) was detected by flow cytometry.
  • the mean fluorescence intensity of cells in the composition solution group of 289WP and 289WP increased by 11.1 and 11.3 times, respectively.
  • the cellular uptake behavior of the prepared composition solution was investigated after being stored at 4°C for 7 days. Compared with the freshly prepared mixture, the cellular uptake of most of the composition solutions decreased, but in the two cells based on 29WP, 289WP
  • the average fluorescence intensity of cells in the composition solution group was still the highest (the effect of 289WP was slightly better than that of 29WP), so peptides 29WP and 289WP were selected as the preferred ocular absorption enhancers to be combined with commercially available ranibizumab injection for subsequent in vivo pharmacokinetics evaluate.
  • a composition of carboxyfluorescein-labeled polypeptide 289WP (289WP-FAM) and Cy5-labeled ranibizumab (Cy5-Rani) was prepared at a molar ratio of 10:1, and their simultaneous uptake in HCEC and ARPE-19 cells was investigated behavior, the results are shown in Figure 9 and Figure 10.
  • Figure 9 shows the simultaneous uptake behavior of polypeptide/antibody in HCEC cells.
  • A is the mean fluorescence intensity of cellular uptake of carboxyfluorescein (FAM)-labeled polypeptide 289WP (289WP-FAM).
  • B is the mean fluorescence intensity of cellular uptake of Cy5-labeled ranibizumab (Cy5-Rani).
  • C is the flow chart of synchronous uptake of 289WP-FAM and Cy5-Rani cells.
  • Figure 10 shows the simultaneous uptake of polypeptides/antibodies in ARPE-19 cells.
  • A is the average fluorescence intensity of cellular uptake of FAM-labeled polypeptide 289WP (289WP-FAM).
  • B is the mean fluorescence intensity of cellular uptake of Cy5-labeled ranibizumab (Cy5-Rani).
  • C is the flow cytogram of synchronous cellular uptake of 289WP-FAM and Cy5-Rani.
  • composition solution group (289W-FAM/Cy5-Rani), the step-up intake group (289WP-FAM, Cy5-Rani), and the fresh mixed group (289WP-FAM+Cy5-Rani) showed no significant difference in HCEC cells.
  • the mean fluorescence intensity values of mixed solution group, step uptake group, and fresh mixed group were 23.2 times, 12.6 times, and 21.3 times higher than those of free antibody, respectively (p ⁇ 0.001).
  • Figure 11 is a mechanism of cellular uptake of polypeptide/ranibizumab compositions.
  • a and B are the effects of temperature and endocytosis inhibitor on the uptake of polypeptides and ranibizumab in HCEC cells and ARPE-19 cells, respectively.
  • Cy5-Rani uptake in 289WP-FAM or the composition (Mixture) without inhibition was used as a control (100%).
  • One-tailed ANOVA was used to analyze significant differences, and Dunnett's test was used for correction (sample size 3, ns p>0.05, *p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001).
  • the nanobodies are fluorescently labeled.
  • FITC fluorescein isothiocyanate
  • the distribution of the polypeptide/Nanobody composition in the mouse eye was investigated by the following method. Precisely weigh 1.0 mg of FITC-labeled nanobody and dissolve it in 120 ⁇ L of normal saline, take out 60 ⁇ L and mix with 0.5 mg of the penetrating peptide 89WP, place it at 4°C for 24 hours, use it as a peptide/nanobody composition, and use the remaining 60 ⁇ L as free nanobody eye drops liquid.
  • mice were administered to the right eye, once every 5 minutes, for a total of 3 times, each dose of 5 ⁇ L.
  • the free Nanobody (Nb) solution contained FITC-labeled Nanobody (green) at a concentration of 8.33 ⁇ g/ ⁇ L
  • the polypeptide/nanobody mixed solution contained polypeptide 89WP and FITC-labeled Nanobody at a concentration of 8.33 ⁇ g/ ⁇ L.
  • the mice were sacrificed 1 hour after the last administration, and the heart was perfused with 40 mL of normal saline.
  • the eyeballs were removed, rinsed with normal saline, fixed in FAS eye fixative solution for 24 hours, dehydrated in a gradient of 15% and 30% sucrose solution, and frozen in cross-section of the eyeball. Sections were stained with DAPI, and the fluorescence signal distribution was observed under a laser confocal microscope.
  • Table 6 shows the corneal distribution of Nanobodies after eye drop.
  • the dosage of free antibody eye drop group or polypeptide/nanobody solution eye drop group was 125 ⁇ g fluorescently labeled Nanobody/eye.
  • ImageJ software was used to calculate the average green fluorescence intensity value of the corneal area (the FITC-labeled nanobody showed green fluorescence).
  • the results showed that compared with the free Nanobody, the 89WP/Nanobody composition was administered by eye drop, which increased the distribution of Nanobody in the corneal site by 3.1 times.
  • Table 7 shows the corneoscleral limbus distribution of Nanobodies after eye instillation.
  • the dosage of free antibody eye drop group or polypeptide/nanobody solution eye drop group was 125 ⁇ g fluorescently labeled Nanobody/eye.
  • ImageJ software was used to calculate the average green fluorescence intensity value of the corneoscleral limbus area (the FITC-labeled nanobody showed green fluorescence).
  • the results showed that, compared with the free nanobody, the 89WP/nanobody composition ophthalmic administration increased the distribution of the nanobody in the corneal and scleral limbus by 3.5 times.
  • Table 8 shows the retinal distribution of Nanobodies after eye instillation.
  • the dosage of free antibody eye drop group or polypeptide/nanobody solution eye drop group was 125 ⁇ g fluorescently labeled Nanobody/eye.
  • ImageJ software was used to calculate the mean green fluorescence intensity value of the retinal area (the FITC-labeled nanobody showed green fluorescence).
  • the results showed that compared with the free nanobody, the 89WP/nanobody composition was administered by eye drop, which increased the distribution of the nanobody in the retina by 4.1 times.
  • the results of semi-quantitative analysis of the green fluorescence signal of the above eye tissue showed that, 1 hour after eye instillation, in the cornea, cornea, scleral limbus adjacent retina, and fundus retina, the green fluorescence signal intensity of the polypeptide/nanobody solution eye instillation group was significantly stronger than that of the free solution.
  • Antibody eye drop group (p ⁇ 0.01) showed that adding polypeptide 89WP to the nanobody solution could significantly increase the intraocular absorption of nanobody after eye drop administration, especially in the fundus and retina distribution.
  • Example 11 Intraocular distribution of the polypeptide/ranibizumab composition after eye drop administration in rabbits
  • a polypeptide/ranibizumab (Rani) solution was prepared. Take a certain amount of commercially available ranibizumab injection (10mg/mL), dilute it to 5mg/mL with an equal volume of commercially available product solvent, and use the resulting solution to dissolve R8 to 4.0mg/mL to obtain R8/Rani mixed solution, or dissolve 89WP To 7.4mg/mL to obtain 89WP/Rani mixed solution, store at 4°C for later use, incubate at 4°C for at least 24h before use, and let stand for 1h at room temperature.
  • ranibizumab injection solvent 10 mM histidine hydrochloride, 10% ⁇ , ⁇ -trehalose, 0.01% Tween 20, pH 5.5.
  • a healthy male rabbit of about 1 kg was selected, and an ophthalmological examination was performed before the experiment to ensure that the eyes were normal.
  • the experimental process followed the experimental animal ethics standards.
  • the rabbits were instilled in 30 ⁇ L of the drug solution in each eye, containing 150 ⁇ g/eye of ranibizumab. Tissue samples were taken 1 h after administration.
  • the rabbits were euthanized, and about 1 mL of blood was immediately drawn from the heart, added to a 1.5 mL anticoagulant tube, centrifuged at 4°C, 2500 g for 15 min, and the supernatant was taken and stored at -20°C for later use; EP tubes, stored at -20°C for later use; isolated retinal tissue, centrifuged at 2500g at 4°C for 10 min, discarded the supernatant, washed twice with 10mM PBS, weighed, and extracted total tissue protein using a total protein extraction kit in 10mM PBS. Store at -20°C for later use.
  • An ELISA detection method was established based on the following steps.
  • Antigen coating dilute hVEGF-A 165 to 1 ⁇ g/mL with coating solution (0.05M carbonate buffer, pH 9.6), and apply the diluted antigen coating solution to each well of the ELISA plate Add 100 ⁇ L, seal the plate and place it at 4°C for overnight coating.
  • coating solution 0.05M carbonate buffer, pH 9.6
  • Blocking Add 250 ⁇ L of blocking solution to each well of the ELISA plate, and incubate at 4°C overnight after sealing.
  • sample containing ranibizumab Take 100 ⁇ L of each sample and add it to the enzyme-labeled well, and incubate at 37°C for 1 h after sealing.
  • Tissue concentrations of ranibizumab were subsequently determined. Prepare the coated antigen (hVEGF-A165) ELISA plate and extracted tissues (plasma, aqueous humor, vitreous body, retinal total protein extract), repeat the above steps 5) to 10), and do the sample accompanying detection of the standard curve at the same time. Tissue concentration of fuzumab.
  • the results of detecting the tissue concentration of ranibizumab by ELISA are as follows.
  • the standard curve was made according to the absorbance value corresponding to the sample concentration.
  • the OD 450nm value detected by ELISA had a good linear relationship with the sample concentration (R 2 >0.98).
  • the ELISA method was feasible to detect the concentration of ranibizumab.
  • FIG. 12 shows the concentration of ranibizumab in each tissue of the rabbit eye 1 h after eye drop administration.
  • Figure 12 shows the concentration of ranibizumab in various tissues (plasma, aqueous humor, vitreous body, retina) in rabbits 1 h after eye drop administration.
  • the shaded area is the median effective concentration (EC 50 ) of ranibizumab reported in the literature.
  • One-tailed ANOVA was used to analyze significant differences, with correction by Tukey's test ( ns p>0.05, *p ⁇ 0.05, **p ⁇ 0.01, compared with Rani group).
  • eye drops are prepared.
  • a peptide/ranibizumab composition take a certain amount of commercially available ranibizumab injection (10mg/mL), dilute it to 5mg/mL with an equal volume of a commercially available product solvent, and dissolve 29WP to 2.48mg/mL with the obtained solution.
  • the composition 29WP/Rani, or the composition 289WP/Rani obtained by dissolving 289WP to 2.54 mg/mL was stored at 4° C. for later use, incubated at 4° C. for at least 24 hours before use, and allowed to stand at room temperature for 1 hour.
  • the dosing and sampling schedule is determined.
  • a healthy male rabbit of about 1 kg was selected, and an ophthalmological examination was performed before the experiment to ensure that the eyes were normal.
  • the experimental process followed the experimental animal ethics standards.
  • 30 ⁇ L of different composition solutions were instilled in each eye of rabbits, containing 150 ⁇ g/eye of ranibizumab. Eye tissue samples were taken at 1h, 4h, 8h, 12h, and 24h after administration.
  • tissue concentration of ranibizumab was determined.
  • the results are as follows: within a given concentration range (5-120ng/mL), the OD 450nm value detected by ELISA has a good linear relationship with the concentration of ranibizumab (R 2 >0.98).
  • the benzumab concentration method is feasible.
  • Figure 13 shows the changes in the concentration distribution of the polypeptide/ranibizumab composition in rabbits after eye drop administration.
  • the dosage: 289WP/Rani composition group contains 289WP 76.2 ⁇ g/eye, ranibizumab 150 ⁇ g/eye; 29WP/Rani composition group contains 29WP 74.4 ⁇ g/eye, ranibizumab 150 ⁇ g/eye; Rani group Contains ranibizumab 150 ⁇ g/eye.
  • the tissue concentration of ranibizumab was detected at 1h, 4h, 8h, 12h and 24h after administration.
  • the shaded area is the median effective concentration (EC 50 ) of ranibizumab reported in the literature.
  • One-tailed ANOVA was used to analyze significant differences, with correction by Tukey's test ( ns p>0.05, *p ⁇ 0.05, **p ⁇ 0.01, compared with Rani group).
  • Table 9 The concentration distribution (ng/mL or ng/g) of peptide-mediated ranibizumab in rabbits after eye drop administration.
  • ranibizumab was detected.
  • the plasma concentrations of 289WP/Rani composition group and 29WP/Rani composition group decreased to 0.9 ⁇ 0.9ng/mL and 14.0 ⁇ 5.0ng/mL.
  • the plasma concentration of ranibizumab was basically 0, indicating that after eye-drop administration, peptide-mediated ranibizumab had a certain systemic absorption, but the plasma concentration of ranibizumab dropped significantly 4 hours after administration, and was basically cleared after 8 hours.
  • ranibizumab in the 289WP/Rani composition group and the 29WP/Rani composition group was in the range of the half effective concentration (EC 50 ) of ranibizumab reported in the literature (9.0-28.8ng/mL), the former was slightly higher, while the ranibizumab concentration in the aqueous humor of the Rani group 1 hour after administration was only 1.7ng/mL, indicating that ranibizumab alone is difficult to achieve effective in the aqueous humor.
  • Therapeutic concentration for the content of ranibizumab in the aqueous humor, 1h and 4h after administration, the concentration of ranibizumab in the 289WP/Rani composition group and the 29WP/Rani composition group was in the range of the half effective concentration (EC 50 ) of ranibizumab reported in the literature (9.0-28.8ng/mL), the former was slightly higher, while the ranibizumab concentration in the aqueous humor of the Rani group 1 hour after administration was only 1.7ng/mL,
  • ranibizumab concentration As for the intravitreal ranibizumab concentration, only the 289WP/Rani composition group could reach the half effective concentration (EC 50 ) of ranibizumab reported in the literature 1 hour after eye instillation (27.0 ⁇ 7.8ng/mL).
  • the distribution of the antibody to the lesions was characterized by the concentration of ranibizumab in the retina. 1h, 4h and 8h after administration, the retinal concentrations of ranibizumab in the 289WP/Rani composition group were 107.1 ⁇ 55.4ng/g and 63.4 ⁇ 43.6ng/g, respectively.
  • the mean values were 20.6, 12.2, and 4.2 times that of the free antibody group, respectively (p ⁇ 0.05), and were higher than or within the range of the half effective concentration (EC 50 ) of ranibizumab reported in the literature , indicating that within 8 hours after a single eye drop administration, the 289WP/Rani composition can maintain the ranibizumab in the retina within the effective concentration range, while 1-8 hours after eye drop administration of the 29WP/Rani composition, the retinal concentration is between 13.7-35.8ng/g can also reach the half effective concentration (EC 50 ) of ranibizumab reported in the literature, but the concentration is low and the duration is short, indicating that the effect of intraocular delivery of ranibizumab in 29WP is not as good as that in 289WP.
  • ranibizumab the concentration in the vitreous or aqueous humor after the peptide/ranibizumab composition is administered by eye drops.
  • the peptide-mediated ranibizumab reaching the retina may be through the conjunctiva ⁇ sclera ⁇ choroid ⁇ Retinal pathway absorption.
  • Example 13 Pharmacokinetics of the polypeptide/aflibercept composition in rabbits after eye-drop administration
  • eye drops are prepared.
  • dilute aflibercept 40mg/mL to 20mg/mL with commercially available aflibercept injection solvent, take this solution to dissolve the polypeptide 289WP to 6.16mg/mL, and store at 4°C For use, incubate at 4°C for at least 24h and let stand for 1h at room temperature before use.
  • aflibercept injection solvent formulation composition 10 mM phosphate buffer solution, 40 mM sodium chloride, 0.03% Tween 20, 5% sucrose, pH 6.2.
  • aflibercept tissue concentrations were determined. Prepare an antigen-coated (hVEGF-A165) ELISA plate and extracted tissue (plasma, aqueous humor, vitreous, retinal total protein extract), repeat steps 5) to 10) in the establishment of the ELISA detection method in Example 11, At the same time, the standard curve of the sample was detected along the way, and the tissue concentration of aflibercept was calculated.
  • hVEGF-A165 antigen-coated
  • the OD 450 nm value detected by ELISA has a good linear relationship with the concentration of aflibercept samples (R 2 >0.98). Within this concentration range, the ELISA method was used. It is feasible to detect the concentration of aflibercept.
  • Figure 14 shows the concentration distribution of the polypeptide/aflibercept solution in rabbits after eye drop administration.
  • the administration dose Afli group contained aflibercept 600 ⁇ g/eye; 289WP/Afli composition group contained 289WP 184.8 ⁇ g/eye, and aflibercept 600 ⁇ g/eye.
  • the tissue concentration of aflibercept was detected 1 h after administration. Two-tailed unpaired t-test was used to analyze significant differences ( ns p>0.05, *p ⁇ 0.05).
  • aflibercept was not detected in the plasma of either the free aflibercept group or the 289WP/Afli composition group at 1 h after administration.
  • the concentration of aflibercept in the aqueous humor (p ⁇ 0.05) and the vitreous body of the 289WP/Afli composition was slightly higher, while the retinal concentration reached 237.6 ⁇ 162.2ng/g, which was significantly higher than that in the Afli group (p ⁇ 0.05).
  • ⁇ 0.05 indicating that polypeptide 289WP can significantly improve the ocular absorption of aflibercept. Similar to peptide/ranibizumab eye drops, aflibercept may be absorbed via the conjunctiva ⁇ sclera ⁇ choroid ⁇ retina route.
  • composition of the present invention can mediate the positively charged drug under the physiological pH condition to efficiently pass through the absorption barrier of the eye, promote the drug to enter the eye and reach the posterior segment of the eye, and further improve the positive charge under the physiological pH condition.
  • the ocular bioavailability of charged drugs significantly promotes cellular uptake of positively charged drugs at physiological pH.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明属药物制剂领域，涉及一种包括野生型穿膜肽penetratin的衍生物和生理pH条件下带正电荷的药物的组合物。所述野生型穿膜肽penetratin的衍生物是一类利用野生型穿膜肽penetratin设计的亲脂性衍生物，在生理pH条件下分子整体带正电荷。本发明所述组合物作为眼部给药系统，可使得生理pH条件下带正电荷的药物通过滴眼的方式吸收到达眼后段，从而为实现生理pH条件下带正电荷的药物的眼部递送提供新途径。

Description

药物和野生型穿膜肽衍生物的组合物 技术领域
本发明属药物制剂领域，涉及用于治疗眼部疾病的组合物，更具体是涉及一种包括野生型穿膜肽penetratin的衍生物和生理pH条件下带正电荷的药物的组合物。
背景技术
穿膜肽(cell-penetrating peptides,CPPs)是一种生理pH条件下带正电荷的短肽，可以介导共价或非共价连接的分子或给药系统(如、脂质体、纳米粒、胶束等)进入细胞(J.Controlled Release,2019,309:106-124)。
由于野生型穿膜肽penetratin的衍生物保留了野生型penetratin在生理pH条件下带正电荷的特性，从而现有技术中认为，野生型穿膜肽penetratin的衍生物通过静电相互作用与生理pH条件下带负电荷的药物结合并实现眼内递送。即，野生型穿膜肽penetratin的衍生物通过静电相互作用可以与生理pH条件下带负电荷的基因、多肽和蛋白质等生物大分子药物自组装形成纳米复合物，或者在聚合物存在的情况下与生理pH条件下带负电荷的基因、多肽和蛋白质等生物大分子药物自组装形成纳米复合物，实现上述生物大分子药物的眼内递送。例如参见中国专利申请CN108976288(A)。
然而，对于生理pH条件下带正电荷的药物，因为其与野生型穿膜肽penetratin的衍生物同样均带有正电荷，一般认为无法通过上述这种方式进行眼内递送给药。因此，现有技术中亟需解决如何促进生理pH条件下带正电的药物在眼内的吸收以及实现所述药物的眼内递送问题。
发明内容
本发明的目的是提供一类人工改造的穿膜肽(cell-penetrating peptides,CPPs)与药物的组合物。
为此，本发明提供了一种用于治疗眼部疾病的组合物，该组合物包括：
(i)生理pH条件下带正电荷的药物，和
(ii)野生型穿膜肽penetratin的衍生物，所述野生型穿膜肽penetratin的衍生物具有下述氨基酸序列：
RX 1IKIWFX 2X 3RRMKWKK
其中，X 1、X 2和X 3代表疏水性氨基酸，选自天然来源的氨基酸丙氨酸(alanine，A)、缬氨酸(valine，V)、亮氨酸(leucine，L)、异亮氨酸(isoleucine，I)、脯氨酸(proline，P)、苯丙氨酸(phenylalanine，F)、色氨酸(tryptophan，W)、甲硫氨酸(methionine，M)和非天然来源的氨基酸α-氨基丁酸(α-aminobutyric acid)、α-氨基戊酸(α-aminopentanoic acid)、α-氨基己酸(α-aminohexanoic acid)、α-氨基庚酸(α-aminoheptanoic acid)，以及它们的组合。
本发明所述用于治疗眼部疾病的组合物，优选所述组合物是溶液或混悬液。
本发明所述的用于治疗眼部疾病的组合物，优选X 1、X 2和X 3代表疏水性氨基酸，X 1、X 2和X 3中的至少两个选自天然来源的氨基酸丙氨酸(alanine，A)、缬氨酸(valine，V)、亮氨酸(leucine，L)、异亮氨酸(isoleucine，I)、脯氨酸(proline，P)、苯丙氨酸(phenylalanine，F)、色氨酸(tryptophan，W)、甲硫氨酸(methionine，M)和非天然来源的氨基酸α-氨基丁酸(α-aminobutyric acid)、α-氨基戊酸(α-aminopentanoic acid)、α-氨基己酸(α-aminohexanoic acid)、α-氨基庚酸(α-aminoheptanoic acid)，以及它们的组合。
本发明所述用于治疗眼部疾病的组合物，优选X 1、X 2或X 3为色氨酸(tryptophan，W)。
本发明所述用于治疗眼部疾病的组合物，优选X 1、X 2或X 3中 的至少两个为色氨酸(tryptophan，W)。
本发明所述用于治疗眼部疾病的组合物，优选所述野生型穿膜肽penetratin的衍生物的氨基酸序列为：
Figure PCTCN2021112687-appb-000001
本发明所述用于治疗眼部疾病的组合物，优选所述野生型穿膜肽penetratin的衍生物的氨基酸序列为：
Figure PCTCN2021112687-appb-000002
本发明所述的用于治疗眼部疾病的组合物，优选所述药物为多肽或蛋白类药物。
本发明所述的用于治疗眼部疾病的组合物，其中优选所述药物选自以下的一种或多种：纳米抗体(Nanobody)、雷珠单抗(Ranibizumab)、阿柏西普(Aflibercept)、奥克纤溶酶(Ocriplasmin)、贝伐单抗(Bevacizumab)、阿达木单抗(Adalimumab)、阿特珠单抗(Atezolizumab)、贝利木单抗(Belimumab)、西妥昔单抗(Cetuximab)、达洛珠单抗(Dalotuzumab)、地诺单抗(Denosumab)、埃罗妥珠单抗(Elotuzumab)、英夫利昔单抗(Infliximab)、伊匹单抗(Ipilimumab)、伊奇珠单抗(Ixekizumab)、那他珠单抗(Natalizumab)、NIST单抗(NISTmab)、纳武单抗(Nivolumab)、奥滨尤妥珠单抗(Obinutuzumab)、奥法木单抗(Ofatumumab)、 帕利珠单抗(Palivizumab)、派姆单抗(Pembrolizumab)、帕妥珠单抗(Pertuzumab)、雷莫芦单抗(Ramucirumab)、利妥昔单抗(Rituximab)、曲妥珠单抗(Trastuzumab)和内皮抑素(Endostatin)。
本发明所述的用于治疗眼部疾病的组合物，优选所述药物选自以下的一种或多种：纳米抗体、雷珠单抗、阿柏西普、奥克纤溶酶、贝伐单抗和西妥昔单抗。
本发明所述的用于治疗眼部疾病的组合物，优选所述药物选自以下的一种或多种：雷珠单抗、阿柏西普和贝伐单抗。
本发明所述的用于治疗眼部疾病的组合物，优选所述纳米抗体选自以下的一种或多种：卡帕珠单抗(Caplacizumab)、奥索拉珠单抗(Ozoralizumab)和伏巴利珠单抗(Vobarilizumab)。
本发明所述的用于治疗眼部疾病的组合物，优选野生型穿膜肽penetratin的衍生物与所述药物的比例为摩尔比为0.1:1-50:1。
本发明所述的用于治疗眼部疾病的组合物，更优选野生型穿膜肽penetratin的衍生物与所述药物的比例为摩尔比为0.5:1-35:1。
本发明所述的用于治疗眼部疾病的组合物，更优选野生型穿膜肽penetratin的衍生物与所述药物的比例为摩尔比为1:1-20:1。
本发明所述的用于治疗眼部疾病的组合物，最优选野生型穿膜肽penetratin的衍生物与所述药物的比例为摩尔比为3:1-15:1。
本发明还提供了一种为需要的受试者治疗眼部疾病的方法，所述方法包括施用治疗有效量的根据本发明所述的用于治疗眼部疾病的组合物。
本发明所述的方法，其中所述方法优选包括将治疗有效量的根据本发明所述的组合物给患者滴眼给药。
本发明还提供了所述的组合物在制备用于治疗眼部疾病的药物中的用途。
附图说明
图1：合成多肽质谱及液相图谱
图2：28WP促进纳米抗体在人角膜上皮细胞中摄取的流式图(左)及平均荧光强度对比(右)。
图3：不同比例的89WP/纳米抗体组合物在人视网膜色素上皮细胞中的摄取。
图4：不同摩尔比条件下，29WP促进奥克纤溶酶在人视网膜色素上皮细胞中的摄取。
图5：不同摩尔比条件下，289WP促进西妥昔单抗在人角膜上皮细胞中的摄取。
图6：不同摩尔比条件下多肽/雷珠单抗组合物细胞摄取定量评价。
图7：不同摩尔比条件下多肽/雷珠单抗组合物细胞摄取定量评价。
图8：不同多肽制备的多肽/雷珠单抗组合物细胞摄取定量评价。
图9：多肽/雷珠单抗组合物在人角膜上皮细胞中同步摄取行为。
图10：多肽/雷珠单抗组合物在人视网膜色素上皮细胞中同步摄取行为。
图11：多肽/雷珠单抗组合物滴眼液细胞摄取机制。
图12：多肽/雷珠单抗组合物滴眼给药1h后兔体内各组织(血浆、房水、玻璃体、视网膜)雷珠单抗浓度。
图13：多肽/雷珠单抗组合物滴眼给药后雷珠单抗在兔体内浓度分布变化。
图14：多肽/阿柏西普组合物滴眼给药后阿柏西普在兔体内浓度分布。
具体实施方式
普通滴眼剂在结膜囊内滞留时间短，吸收效果差，特别是基因、多肽和蛋白质等生物大分子药物经局部滴眼给药后，眼部生物利用度 极低，并且几乎不能到达眼后段；眼内注射剂和眼内植入剂生物利用度虽高，但患者顺应性差，且容易导致严重的并发症。
为了解决现有技术中的上述缺陷，本发明将经人工改造的穿膜肽作为眼部吸收促进剂，可通过非创伤途径滴眼给药，通过非共价连接将在生理pH条件下带正电荷的药物递送至眼内。所述穿膜肽是一种生理pH条件下带正电荷的短肽，而所述药物为在生理pH条件下带正电荷的药物。申请人意想不到地发现，所述生理pH条件下带正电荷的穿膜肽和所述生理pH条件下带正电荷的药物的组合物可以显著促进细胞的摄取。与仅使用所述生理pH条件下带正电荷的药物的情况比较，所述组合物使得细胞摄取显著增加。
本发明提供了一种用于治疗眼部疾病的组合物，该组合物包括：(i)生理pH条件下带正电荷的药物，和(ii)野生型穿膜肽penetratin的衍生物。所述野生型穿膜肽penetratin的衍生物为基于天然来源的穿膜肽penetratin，采用氨基酸突变的方法，设计并制备的一系列对眼组织穿透性好、生物安全性高的多肽衍生物，可通过非创伤途径将与其混合的生理pH条件下带正电荷的药物递送至眼内。通过本发明的组合物，能够介导所述生理pH条件下带正电荷的药物高效地透过眼部的吸收屏障，促进药物进入眼内并到达眼后段，进而提高生理pH条件下带正电荷的药物的眼部生物利用度。
所述野生型多肽penetratin的氨基酸序列如下：
RQIKIWFQNRRMKWKK
野生型penetratin对眼组织的穿透能力随着分子的疏水性增强而得到改善。因此，本发明所述penetratin衍生物在保持野生型penetratin基本氨基酸序列不变的前提下，利用氨基酸突变技术，在其分子中引入疏水性氨基酸，进而增强所得到的penetratin衍生物的眼组织穿透能力。
具体地说，本发明是在野生型penetratin的基础之上，保持其原有碱性氨基酸精氨酸(arginine，R)、赖氨酸(lysine，K)以及原有疏水氨基酸异亮氨酸(isoleucine，I)、苯丙氨酸(phenylalanine， F)、色氨酸(tryptophan，W)、甲硫氨酸(methionine，M)的序列不变，利用多肽固相合成技术，以疏水性氨基酸取代penetratin分子中的亲水性氨基酸谷氨酰胺(glutamine，Q)和天冬酰胺(asparagine，N)，进而得到一系列多肽衍生物。
所述penetratin衍生物的特征在于对野生型penetratin不同亲水性氨基酸(谷氨酰胺和天冬酰胺)位点用不同的疏水性氨基酸进行取代。所述疏水性氨基酸选自天然来源的氨基酸丙氨酸(alanine，A)、缬氨酸(valine，V)、亮氨酸(leucine，L)、异亮氨酸(isoleucine，I)、脯氨酸(proline，P)、苯丙氨酸(phenylalanine，F)、色氨酸(tryptophan，W)、甲硫氨酸(methionine，M)和非天然来源的氨基酸α-氨基丁酸(α-aminobutyric acid)、α-氨基戊酸(α-aminopentanoic acid)、α-氨基己酸(α-aminohexanoic acid)、α-氨基庚酸(α-aminoheptanoic acid)等，以及它们的组合。
在野生型penetratin基础之上进行结构改造得到的多肽衍生物，其氨基酸序列如表1所示，其中，突变的氨基酸用下划线标示。该表格中未给出非天然氨基酸突变的实例，不同疏水氨基酸的组合突变仅给出代表性实例。
penetratin衍生物对眼组织的穿透能力与其疏水性(亲脂性)相关，疏水性(亲脂性)越强，penetratin衍生物对眼组织的穿透能力也越强。因此，利用其它疏水性氨基酸制备的penetratin衍生物也将获得增强的眼部吸收促进效果。
本发明中所述penetratin衍生物相对于因安全性问题极少在眼部应用的小分子吸收促进剂，这种多肽类吸收促进剂易于降解，因而生物安全性更好。另一方面，多肽类吸收促进剂易于修饰和改造，以实现不同的应用目标，而且本发明所述的penetratin衍生物较天然来源的野生型penetratin具有更强的眼部吸收促进能力。
表1.野生型penetratin经结构改造后得到的penetratin衍生物
缩写 氨基酸序列 缩写 氨基酸序列
2-A R AIKIWFQNRRMKWKK 2-V R VIKIWFQNRRMKWKK
8-A RQIKIWF ANRRMKWKK 8-V RQIKIWF VNRRMKWKK
9-A RQIKIWFQ ARRMKWKK 9-V RQIKIWFQ VRRMKWKK
28-A R AIKIWF ANRRMKWKK 28-V R VIKIWF VNRRMKWKK
29-A R AIKIWFQ ARRMKWKK 29-V R VIKIWFQ VRRMKWKK
89-A RQIKIWF AARRMKWKK 89-V RQIKIWF VVRRMKWKK
289-A R AIKIWF AARRMKWKK 289-V R VIKIWF VVRRMKWKK
2-L R LIKIWFQNRRMKWKK 2-I R IIKIWFQNRRMKWKK
8-L RQIKIWF LNRRMKWKK 8-I RQIKIWF INRRMKWKK
9-L RQIKIWFQ LRRMKWKK 9-I RQIKIWFQ IRRMKWKK
28-L R LIKIWF LNRRMKWKK 28-I R IIKIWF INRRMKWKK
29-L R LIKIWFQ LRRMKWKK 29-I R IIKIWFQ IRRMKWKK
89-L RQIKIWF LLRRMKWKK 89-I RQIKIWF IIRRMKWKK
289-L R LIKIWF LLRRMKWKK 289-I R IIKIWF IIRRMKWKK
2-P R PIKIWFQNRRMKWKK 2-F R FIKIWFQNRRMKWKK
8-P RQIKIWF PNRRMKWKK 8-F RQIKIWF FNRRMKWKK
9-P RQIKIWFQ PRRMKWKK 9-F RQIKIWFQ FRRMKWKK
28-P R PIKIWF PNRRMKWKK 28-F R FIKIWF FNRRMKWKK
29-P R PIKIWFQ PRRMKWKK 29-F R FIKIWFQ FRRMKWKK
89-P RQIKIWF PPRRMKWKK 89-F RQIKIWF FFRRMKWKK
289-P R PIKIWF PPRRMKWKK 289-F R FIKIWF FFRRMKWKK
2-W R WIKIWFQNRRMKWKK 2-M R MIKIWFQNRRMKWKK
8-W RQIKIWF WNRRMKWKK 8-M RQIKIWF MNRRMKWKK
9-W RQIKIWFQ WRRMKWKK 9-M RQIKIWFQ MRRMKWKK
28-W R WIKIWF WNRRMKWKK 28-M R MIKIWF MNRRMKWKK
29-W R WIKIWFQ WRRMKWKK 29-M R MIKIWFQ MRRMKWKK
89-W RQIKIWF WWRRMKWKK 89-M RQIKIWF MMRRMKWKK
289-W R WIKIWF WWRRMKWKK 289-M R MIKIWF MMRRMKWKK
2-A,8-V R AIKIWF VNRRMKWKK 2-F,9-W R FIKIWFQ WRRMKWKK
2-V,8-A R VIKIWF ANRRMKWKK 2-W,9-F R WIKIWFQ FRRMKWKK
2-V,9-L R VIKIWFQ LRRMKWKK 2-W,9-M R WIKIWFQ MRRMKWKK
2-L,9-V R LIKIWFQ VRRMKWKK 2-M,9-W R MIKIWFQ WRRMKWKK
2-L,9-I R LIKIWFQ IRRMKWKK 2-M,8-W,9-Y R MIKIWF WYRRMKWKK
2-I,9-L R IIKIWFQ LRRMKWKK 2-W,8-Y,9-P R WIKIWF YPRRMKWKK
2-I,8-P R IIKIWF PNRRMKWKK 2-Y,8-P,9-I R YIKIWF PIRRMKWKK
2-P,8-I R PIKIWF INRRMKWKK 2-P,8-I,9-L R PIKIWF ILRRMKWKK
2-P,8-F R PIKIWF FNRRMKWKK 2-I,8-L,9-V R IIKIWF LVRRMKWKK
2-F,8-P R FIKIWF PNRRMKWKK 2-L,8-V,9-A R LIKIWF VARRMKWKK
在本领域中，等电点(isoelectric point,pI)是指分子如蛋白质或多肽的净电荷为零的pH值。例如参见文献：Kentaro Tomii.Protein Properties.Encyclopedia of Bioinformatics and Computational Biology.2019,2:28-33.(doi:10.1016/B978-0-12-809633-8.20266-5)。由于两性离子所带电荷因溶液的pH值不同而改变，当两性离子正负电荷数值相等时，溶液的pH值即其等电点。本发明中所述在生理pH条件下带正电荷的药物，即等电点高于7.45的药物，如多肽或蛋白药物。
在本领域中，生理pH条件是指：在生理状态下，人体的pH范围介于7.35至7.45,平均值为7.40。人体中血液的pH值维持在7.4±0.03很窄的范围。例如参见文献：Hopkins E,Sharma S.Physiology,Acid Base Balance.In:StatPearls[Internet].StatPearls Publishing；Treasure Island(FL):Jun 16,2019.PMID:29939584；以及Melvin E.Laski,Neil A.Kurtzman.Acid-base disorders in medicine.Disease-a-Month.1996,42(2):59-125。由于本发明中药物的等电点高 于生理状态下人体的pH范围，因此在所述生理pH条件下所述药物带正电荷。
表2.在生理pH条件下带正电荷的药物
药物名称 等电点 分子量(千道尔顿，kD)
阿柏西普 8.8 115
阿达木单抗 8.9 148
阿特珠单抗 8.6 145
贝利木单抗 8.6 147
贝伐单抗 8.3 149
卡帕珠单抗 9.2 28
西妥昔单抗 8.8 152
达洛珠单抗 9.0 146
地诺单抗 8.9 147
埃罗妥珠单抗 8.0 148
英夫利昔单抗 7.6 149
伊匹单抗 9.2 148
伊奇珠单抗 8.1 146
那他珠单抗 7.8 149
纳米抗体 9.6 13
NIST单抗 9.2 150
纳武单抗 8.0 146
奥滨尤妥珠单抗 8.6 146
奥法木单抗 9.0 149
奥克纤溶酶 7.7 27
奥索拉珠单抗 8.8 38
帕利珠单抗 9.3 148
派姆单抗 7.6 149
帕妥珠单抗 9.0 148
雷莫芦单抗 9.1 147
雷珠单抗 8.8 48
利妥昔单抗 9.4 145
曲妥珠单抗 9.1 145
伏巴利珠单抗 8.7 26
本发明组合物可以通过以下方式获得：
将野生型穿膜肽penetratin的衍生物与生理pH条件下带正电荷的多肽或蛋白质药物通过物理混合制备而成。
发明人发现，通过物理混合获得的本发明组合物可以促进蛋白药物在眼内的吸收。发明人通过细胞摄取实验，对本发明的组合物在体外促进细胞摄取的效果进行了比较。结果显示，penetratin衍生物与在生理pH条件下带正电的蛋白药物的摩尔比在0.1:1-50范围内的组合物可以获得蛋白药物在眼内的良好吸收。并且在penetratin衍生物中，双突变(28WP、29WP、89WP)和三突变(289WP)衍生物促进吸收效果更好。
所述生理pH条件下带正电的蛋白药物包括雷珠单抗，等电点8.8；贝伐单抗，等电点8.8；和阿柏西普，等电点8.2。所述组合物特别在摩尔比介于5:1至35:1时具有最佳的促进吸收效果。
纳米抗体是一类新颖而独特的抗原结合片段，来自于天然存在于羊驼血清中的重链抗体。纳米抗体是重组的、单一结构域的可变片段，来源于羊驼的重链抗体，可选择性地与特定抗原结合。例如参见文献：
Figure PCTCN2021112687-appb-000003
I,Muyldermans S.The Therapeutic Potential of Nanobodies.BioDrugs.2020,34:11-26；Rubel Chakravarty,Shreya Goel,Weibo Cai.Nanobody:The“Magic Bullet”for Molecular Imaging？Theranostics 2014；4(4):386-398。
常见的纳米抗体包括：Caplacizumab(通用名ALX 0681或ALX-0081，商品名Cablivi)，分子量28kDa，等电点9.2；Ozoralizumab(通用名ATN-103)，分子量38kDa，等电点8.8；Vobarilizumab(通用名ALX-0061)，分子量26kDa，等电点8.7。
本发明已经在小鼠体内证实，通过滴眼给药所述组合物，可以将纳米抗体递送到眼内(包括眼前段的角膜和眼后段的视网膜)。在单独使用纳米抗体的情况下，则几乎不产生吸收。
具体地，与不含野生型穿膜肽penetratin的衍生物89WP只含有纳米抗体的药物比较，包括89WP与纳米抗体且二者的摩尔比范围 为5:1～50:1的组合物的细胞摄取显著增加。当89WP与纳米抗体的摩尔比为10:1-15:1时，获得了最佳的促进摄取效果。如图3所示，通过对89WP与纳米抗体二者的比例(89WP:纳米抗体)分别为5:1、10:1、15:1、20:1、25:1、30:1、35:1、40:1、45:1和50:1的组合物进行比较。结果显示，89WP:纳米抗体为10:1和15:1的两组组合物获得了最多的细胞摄取。
同样，通过将包括89WP和雷珠单抗的组合物滴眼给药给家兔，证明了在家兔体内可以通过所述组合物将雷珠单抗递送到眼内(包括眼后段的视网膜和玻璃体)。效果显著优于对照R8。
其中，R8为8聚精氨酸(arginine，R)的缩写，是一种经典的人工合成穿膜肽。有文献报道用R8的同系物6聚精氨酸(R6)将雷珠单抗和贝伐单抗通过滴眼给药递送到小鼠眼内。例如参见：Invest Ophthalmol Vis Sci.2017；58(5):2578-2590.doi:10.1167/iovs.16-20072.。还有文献报道，R8比R6有更好的促进吸收效果。例如参见：J Control Release.2007；118(2):177-84.doi:10.1016/j.jconrel.2006.12.022。
在本发明中，发明人用R8做对照，证明本发明的效果优于R8，从而证明本发明获得了优于文献报道中的R6的技术效果。如果不加89WP则不产生吸收。
具体地，利用细胞摄取实验在体外筛选野生型穿膜肽penetratin的衍生物(R6(6聚精氨酸)、野生型Penetratin、2WP、8WP、9WP、28WP、29WP、89WP、289WP)与雷珠单抗的组合物，摩尔比设定为10:1，选用了2种不同的细胞，其中29WP、289WP效果最好，与不含野生型穿膜肽penetratin的衍生物只含有雷珠单抗的组合物比较，细胞摄取显著增加。
与含有文献报道(例如参见：Invest Ophthalmol Vis Sci.2017；58(5):2578-2590.doi:10.1167/iovs.16-20072.，其中6聚精氨酸(R6)将雷珠单抗和贝伐单抗通过滴眼给药递送到小鼠眼内)具有吸收促进作用的多肽R6和雷珠单抗的组合物比较(R6:雷珠单抗的比例与野 生型穿膜肽penetratin的衍生物:雷珠单抗的比例相同)，以及与含有野生型Penetratin和雷珠单抗的组合物比较(野生型Penetratin:雷珠单抗的比例与野生型穿膜肽penetratin的衍生物:雷珠单抗的比例相同)，细胞摄取显著增加。如图6所示，细胞摄取分别增加13.5、14.7倍。
利用细胞摄取实验在体外筛选89WP与雷珠单抗的组合物，选用了3种不同的细胞，二者摩尔比变化范围5:1～18:1，与不含89WP只含有雷珠单抗的组合物比较，细胞摄取显著增加。与含有文献报道具有吸收促进作用的多肽R8和雷珠单抗的组合物比较(R8:雷珠单抗的比例介于5:1-30:1，高于89WP:雷珠单抗的比例)，细胞摄取显著增加。如图4和图5所示，细胞摄取增加了2.2-6.7倍。
利用细胞摄取实验在体外筛选289WP与雷珠单抗的组合物，选用了2种不同的细胞，证实289WP与雷珠单抗形成组合物(摩尔比10:1)后，二者同步被细胞摄取。
利用细胞摄取实验在体外筛选29WP和289WP与雷珠单抗的组合物，分别利用29WP和289WP与雷珠单抗形成复合物(摩尔比10:1)，在家兔体内证实通过滴眼给药可以将雷珠单抗递送到眼内(包括眼前段的房水，眼后段的视网膜和玻璃体)。如果不加野生型穿膜肽penetratin的衍生物，雷珠单抗几乎不吸收。在这种情况下，发明人意想不到地发现，野生型穿膜肽penetratin的衍生物能够与在生理pH条件下带正电荷的雷珠单抗产生相互作用，并且野生型穿膜肽penetratin的衍生物能够将雷珠单抗带入到眼内。利用细胞摄取实验在体外筛选289WP与阿柏西普的组合物。其中，利用289WP与阿柏西普形成组合物(摩尔比10:1)，在家兔体内证实通过滴眼给药可以将阿柏西普递送到眼内(包括眼前段的房水，眼后段的视网膜和玻璃体)。如果不加野生型穿膜肽penetratin的衍生物，阿柏西普几乎不吸收。
通过本发明的组合物，获得了意想不到的技术效果。具体地，本发明组合物中的penetratin衍生物保留了野生型penetratin在生理 pH条件下带正电荷的特性，通过与生理pH条件下带正电荷的药物通过非共价方式形成组合物，意想不到地实现了上述药物的更好的眼内递送。
例如，通过在小鼠体内施用所述组合物，本发明证实了通过滴眼给药，所述组合物可以将药物如纳米抗体递送到眼内，包括将药物如纳米抗体递送到眼前段的角膜和眼后段的视网膜。通过在兔体内施用所述组合物，本发明证实了通过滴眼给药，所述组合物可以将药物如雷珠单抗和阿柏西普递送到眼内，包括将药物如雷珠单抗和阿柏西普递送到眼前段的角膜和眼后段的视网膜。在仅施用该药物而不包括所述野生型穿膜肽penetratin的衍生物的情况下，无法获得该递送效果。
实施例
以下结合本发明的具体实施例进一步阐明本发明，但并不限制其保护范围。
实施例1.野生型穿膜肽penetratin衍生物的合成、纯化及表征
采用固相合成技术进行多肽合成，多肽序列如表3所示。
采用制备液相对冻干后粗品进行纯化，制备柱为Waters XBridge TM BEH130 Prep C18柱(19×250mm，10μm)，冻干后进行后续纯度及分子量表征。
表3多肽序列信息
名称 缩写 序列 理论分子量 *
Penetratin Pe RQIKIWFQNRRMKWKK 2246.75
Q2W-Penetratin 2WP RWIKIWFQNRRMKWKK 2304.84
Q8W-Penetratin 8WP RQIKIWFWNRRMKWKK 2304.84
N9W-Penetratin 9WP RQIKIWFQWRRMKWKK 2318.86
Q2W,Q8W-Penetratin 28WP RWIKIWFWNRRMKWKK 2362.92
Q2W,N9W-Penetratin 29WP RWIKIWFQWRRMKWKK 2376.95
Q8W,N9W-Penetratin 89WP RQIKIWFWWRRMKWKK 2376.95
Q2W,Q8W,N9W-Penetratin 289WP RWIKIWFWWRRMKWKK 2435.03
Poly(argnine) 6 R6 RRRRRR 955.14
*：采用PeptideMass计算工具求得多肽的理论平均分子量， https://web.expasy.org/peptide_mass/
采用高效液相色谱法考察多肽纯度，色谱条件如下，
色谱柱：YMC-Pack ODS-A柱(4.6×150mm,5μm)；
柱温：20℃；
流动相：A相为纯水(含0.1％TFA)，B相为乙腈(含0.1％TFA)，野生型穿膜肽penetratin的衍生物流动相方法为5-65％B，30min，多肽R6则为2-32％B，30min；
流速：0.7mL/min；
检测波长：214nm。
采用电喷雾电离质谱(ESI-MS)考察多肽分子量，检测条件如下，
流动相：甲醇:纯水:甲酸＝80:19.9:0.1；
流速：0.3mL/min；
毛细管电压：3000V；
干燥气体温度及流速：350℃，12L/min。
多肽纯度及分子量见表4，具体谱图信息详见图1。所有多肽液相纯度均在95％以上，分子量正确，可用于后续实验。
表4多肽液相纯度及分子量
名称 纯度(214nm) 实测分子量
Pe 96.47％ 2246.40
2WP 95.94％ 2304.00
8WP 98.11％ 2304.80
9WP 97.84％ 2318.40
28WP 95.71％ 2362.20
29WP 99.22％ 2376.80
89WP 96.16％ 2377.00
289WP 97.65％ 2434.20
R6 95.81％ 955.20
实施例2.多肽促进纳米抗体被眼部细胞摄取
取适量纳米抗体(等电点9.6，分子量13kD)溶于100mM Na 2CO 3溶液，加入荧光标记试剂Sulfo-Cy5-NHS，4℃条件下搅拌反应过夜，体系于4℃纯水中透析后冻干，即得荧光探针Cy5标记的纳米抗体。
多肽28WP与Cy5标记的纳米抗体分别溶解于磷酸缓冲溶液(PBS，浓度10mM，pH7.4)中，将28WP溶液与Cy5标记的纳米抗体溶液按摩尔比5:1混合，室温条件下放置24h，得到28WP与纳米抗体组合物。
取生长状态良好的人角膜上皮细胞(HCEC)，按1×10 4细胞/孔铺于24孔板，培养24h后，弃去培液，加入28WP与纳米抗体组合物(含Cy5标记的纳米抗体浓度为1μM)，37℃孵育2h，弃去药液，用10mM PBS(含0.02mg/mL肝素钠)洗3次，收集细胞，重悬于10mM PBS，流式细胞仪进行检测。
由图2可见，游离纳米抗体自身很难被人角膜上皮细胞摄取。多肽28WP与纳米抗体形成的组合物与细胞孵育后，纳米抗体的细胞摄取显著改善，较游离纳米抗体的细胞摄取增加至19.4倍。
实施例3.不同比例多肽/纳米抗体组合物的细胞摄取
按照表5中比例配制89WP/纳米抗体滴眼液，4℃孵育过夜，备用。
表5. 89WP/纳米抗体滴眼液组合物
Figure PCTCN2021112687-appb-000004
Figure PCTCN2021112687-appb-000005
将ARPE-19细胞铺于24孔板，培养24h以上。弃去培液，每孔加入200μL药液及300μL无血清培液，孵育2h后，弃去药液，PBS洗3次，将细胞消化并重悬于PBS中，流式检测Cy5荧光信号(Ex 645nm，Em 665nm)。
89WP与纳米抗体摩尔比从5:1至50:1条件下的细胞摄取见图3。
图3为不同比例的89WP/纳米抗体组合物在ARPE-19细胞中的摄取。其中，89WP与纳米抗体的摩尔比分别为5:1,10:1,15:1,20:1,25:1,30:1,35:1,40:1,45:1,50:1。
结果表明，在该比例范围内，89WP可以显著促进纳米抗体的细胞摄取，在摩尔比10:1-30:1范围内促进摄取效果较好。因此，优选的89WP与纳米抗体摩尔比范围为5:1至35:1，更进一步优选10:1至30:1。
实施例4.多肽促进奥克纤溶酶被眼部细胞摄取
多肽29WP与Cy5标记的奥克纤溶酶(Ocriplasmin，等电点7.7，分子量27kD)分别溶解于柠檬酸缓冲溶液(浓度0.53mg/mL)中，将29WP溶液与Cy5标记的奥克纤溶酶溶液按摩尔比0.1:1、0.3:1、0.5:1、0.7:1、0.9:1和1:1混合，室温条件下放置24h，得到29WP与奥克纤溶酶组合物。
取生长状态良好的人视网膜色素上皮细胞(ARPE-19)，按1×10 4细胞/孔铺于24孔板，培养24h后，弃去培液，加入含有不同29WP与奥克纤溶酶摩尔比的组合物(含Cy5标记的奥克纤溶酶浓度为1μM)，37℃孵育2h，弃去药液，用10mM PBS(含0.02mg/mL肝素钠)洗3次，收集细胞，重悬于10mM PBS，流式细胞仪进行检测。
由图4可见，在摩尔比0.1:1至1:1条件下，多肽29WP与奥克纤溶酶形成的组合物可以使奥克纤溶酶在人视网膜色素上皮细胞中的摄 取增加7至21倍。
实施例5.多肽促进西妥昔单抗被眼部细胞摄取
多肽289WP与Cy5标记的西妥昔单抗(Cetuximab，等电点8.8，分子量152kD)分别溶解于磷酸缓冲溶液(PBS，浓度10mM，pH7.4)中，将289WP溶液与Cy5标记的西妥昔单抗溶液按摩尔比0.5:1、0.7:1、1:1、3:1、5:1、7:1和10:1混合，室温条件下放置24h，得到289WP与西妥昔单抗组合物。
取生长状态良好的人角膜上皮细胞(HCEC)，按1×10 4细胞/孔铺于24孔板，培养24h后，弃去培液，加入含有不同289WP与西妥昔单抗摩尔比的组合物(含Cy5标记的西妥昔单抗浓度为1μM)，37℃孵育2h，弃去药液，用10mM PBS(含0.02mg/mL肝素钠)洗3次，收集细胞，重悬于10mM PBS，流式细胞仪进行检测。
由图5可见，在摩尔比0.5:1至10:1条件下，多肽289WP与西妥昔单抗形成的组合物可以使西妥昔单抗在人角膜上皮细胞中的摄取增加12至32倍。
实施例6.不同比例多肽/雷珠单抗组合物的细胞摄取
首先，对雷珠单抗进行荧光标记。取一定量雷珠单抗注射液，4℃纯水中透析3d脱盐(截留分子量10kD)，冻干后取5mg复溶于100mM Na 2CO 3溶液中，加入0.12mg荧光标记试剂Sulfo-Cy5-NHS，4℃条件下搅拌反应过夜，体系于4℃纯水中透析3d后冻干，即得荧光标记雷珠单抗(Cy5-Rani)。
随后制备多肽/雷珠单抗组合物。称取适量多肽，用一定体积市售雷珠单抗注射剂溶解，再加入等体积市售雷珠单抗注射液溶剂，4℃保存，备用。
对不同的多肽/雷珠单抗组合物摄取效果进行评价。取生长状态良好的HCEC、ARPE-19和HUVEC细胞，按1×10 4细胞/孔分别铺于 24孔板，培养24h后，弃去培液，加入不同组合物多肽/Cy5-Rani混合物溶液(均含Cy5-Rani 1μM)，37℃孵育2h，弃去药液，用10mM PBS(含0.02mg/mL肝素钠)洗3次，收集细胞，重悬于10mM PBS，流式检测阳性细胞率和平均荧光强度，检测通道激发波长638nm，发射波长660nm。
不同摩尔比条件下多肽介导的抗体细胞摄取结果如下。以眼部渗透能力较强的多肽89WP与Cy5标记雷珠单抗(Cy5-Rani)按不同摩尔比混合后，考察其细胞摄取行为，结果如图6、图7所示。
图6为不同摩尔比条件下多肽介导雷珠单抗细胞摄取定量评价。其中，取一定量多肽按不同摩尔比(89WP/Rani,1:1,3:1,5:1,7:1,10:1；R8/Rani,5:1,15:1,30:1)与Cy5标记雷珠单抗1μM混合，4℃孵育24h，然后与不同细胞在37℃条件下共孵育2h。采用One-Way ANOVA检验进行显著性分析，以Dunnett’s检验校正(n＝3, nsp>0.05,***p<0.001,与游离雷珠单抗比较)。
图7为不同摩尔比条件下多肽介导雷珠单抗细胞摄取的定量评价。其中，取一定量多肽89WP按不同摩尔比(5:1,7:1,10:1,12:1,15:1,18:1)与Cy5标记雷珠单抗1μM混合，4℃孵育24h，然后与不同细胞在37℃条件下共孵育2h。采用One-Way ANOVA检验进行显著性分析，以Tukey’s检验校正(n＝3, nsp>0.05,*p<0.05,**p<0.01,***p<0.001)。
结果表明，在摩尔比1:1至10:1条件下，多肽介导雷珠单抗细胞摄取呈上升趋势。根据初步筛选结果进一步优化89WP与雷珠单抗的摩尔比，在5:1至18:1条件下，与游离抗体相比，多肽89WP介导抗体在3种细胞中摄取量增加2.2-6.7倍(p<0.001)；随多肽用量增加，抗体细胞摄取量总体呈上升趋势，在HCEC细胞中，摩尔比10:1条件下抗体细胞摄取量与摩尔比7:1、12:1无显著性差异(p>0.05)，在ARPE-19细胞中，摩尔比10:1条件下抗体细胞摄取量显著高于摩尔比7:1混合物(p<0.001)，较低于摩尔比12:1混合物(p<0.01)，在HUVEC细胞中，摩尔比10:1条件下抗体细胞摄取量显著高于摩尔比7:1混合物(p<0.001)，与摩尔比12:1混合物无显著性差异(p>0.05)， 略低于摩尔比15:1混合物(p<0.05)。总体上摩尔比10:1条件下多肽介导抗体细胞摄取量较低摩尔比组合物显著增加，此后继续增加多肽用量，抗体细胞摄取量增速趋缓，为提高多肽利用率，最终确定摩尔比10:1为最优组合物处方。
实施例7.不同多肽/雷珠单抗组合物的细胞摄取
在摩尔比10:1条件下制备不同多肽和雷珠单抗组合物，考察其在HCEC和ARPE-19细胞中摄取行为，结果如图6所示。
图8为不同多肽介导雷珠单抗细胞摄取的定量评价。其中，取不同多肽10μM与1μM Cy5-Rani混合，4℃孵育24h得到组合物溶液，将组合物溶液与不同细胞在37℃孵育2h后检测，或将组合物溶液在4℃保存7天后与细胞孵育，流式检测细胞平均荧光强度值(Ex 638nm/Em 660nm)。
结果表明，在2种细胞模型中，野生型Penetratin介导雷珠单抗细胞摄取量均低于其含疏水衍生肽组合物溶液的细胞摄取量，并且衍生肽亲脂性增强，介导雷珠单抗细胞摄取量呈上升趋势。在HCEC细胞中，多肽29WP、289WP介导雷珠单抗细胞摄取能力最强，相比于游离抗体，平均荧光强度分别增加13.5、14.7倍，在ARPE-19细胞中有相同结果，基于多肽29WP、289WP的组合物溶液组细胞平均荧光强度分别增加11.1、11.3倍。将所制备组合物溶液于4℃条件下保存7d后考察其细胞摄取行为，与新鲜制备混合物相比，总体上大部分组合物溶液细胞摄取有所下降，但在2种细胞中基于29WP、289WP组合物溶液组细胞平均荧光强度仍为最高(289WP效果略优于29WP)，因此选择多肽29WP、289WP为优选眼部吸收促进剂与市售雷珠单抗注射液组合，进行后续体内药动学评价。
实施例8.多肽/雷珠单抗组合物的细胞摄取机制
在本实施例中对多肽与雷珠单抗的同步细胞摄取行为进行研究。
在摩尔比10:1条件下制备羧基荧光素标记的多肽289WP(289WP-FAM)和Cy5标记的雷珠单抗(Cy5-Rani)组合物，考察二者在HCEC和ARPE-19细胞中同步摄取行为，结果如图9、图10所示。
图9为多肽/抗体在HCEC细胞中的同步摄取行为。A为羧基荧光素(FAM)标记多肽289WP(289WP-FAM)的细胞摄取平均荧光强度。B为Cy5标记雷珠单抗(Cy5-Rani)的细胞摄取平均荧光强度。C为289WP-FAM和Cy5-Rani细胞同步摄取流式图。各组合物均含289WP-FAM 10μM、Cy5-Rani 1μM，溶于市售雷珠单抗注射液溶剂中，均与细胞37℃共孵育后(289WP-FAM/Cy5-Rani组，两者混合4℃孵育24h后与细胞共孵育1.5h；289WP-FAM,Cy5-Rani组，289WP-FAM与细胞共孵育1.5h，弃去，Cy5-Rani继续与细胞共孵育1.5h；289WP-FAM+Cy5-Rani组，两者混合后立即与细胞共孵育1.5h)进行流式检测(FAM，Ex 488nm/Em 520nm；Cy5，Ex 638nm/Em 660nm)。采用One-Way ANOVA检验进行显著性分析，以Tukey’s检验校正(n＝3, nsp>0.05,***p<0.001)。
图10为多肽/抗体在ARPE-19细胞中同步摄取行为。其中，A为FAM标记多肽289WP(289WP-FAM)的细胞摄取平均荧光强度。B为Cy5标记雷珠单抗(Cy5-Rani)的细胞摄取平均荧光强度。C为289WP-FAM和Cy5-Rani的细胞同步摄取流式图。各组合物均含289WP-FAM 10μM、Cy5-Rani 1μM，溶于市售雷珠单抗注射液溶剂中，均与细胞37℃共孵育后(289WP-FAM/Cy5-Rani组，两者混合4℃孵育24h后与细胞共孵育1.5h；289WP-FAM,Cy5-Rani组，289WP-FAM与细胞共孵育1.5h，弃去，Cy5-Rani继续与细胞共孵育1.5h；289WP-FAM+Cy5-Rani组，两者混合后立即与细胞共孵育1.5h)进行流式检测(FAM，Ex 488nm/Em 520nm；Cy5，Ex 638nm/Em 660nm)。采用One-Way ANOVA检验进行显著性分析，以Tukey’s检验校正(n＝3, nsp>0.05,*p<0.05,***p<0.001)。
结果表明，对于多肽(289WP-FAM)细胞摄取，在HCEC细胞中，各组细胞平均荧光强度值无显著性差异，而在ARPE-19细胞中，对于 289WP-FAM细胞摄取，组合物溶液组平均荧光强度是游离多肽的9/10，其余组则与游离多肽无显著性差异，表明单独给以多肽或将多肽与抗体组合后给药，两种细胞对于多肽289WP-FAM摄取均变化不大，抗体对多肽细胞摄取基本无影响。而与游离抗体相比，组合物溶液组(289W-FAM/Cy5-Rani)、分步摄取组(289WP-FAM,Cy5-Rani)、新鲜混合组(289WP-FAM+Cy5-Rani)在HCEC细胞中摄取平均荧光强度分别是其23.2倍、12.6倍、21.3倍(p<0.001)，而对于ARPE-19细胞，混合溶液组、分步摄取组、新鲜混合组平均荧光强度值分别是游离抗体的7.4倍、5.3倍、6.2倍(p<0.001)，表明多肽与抗体同步给药，或先以多肽处理细胞，继之给以抗体，均可大幅改善抗体细胞摄取效果(p<0.001)，但同步给药优于分步给药(p<0.001)。
实施例9.多肽/雷珠单抗组合物的细胞内吞机制
在不同温度或添加内吞抑制剂条件下，采用流式细胞术考察多肽289WP与雷珠单抗组合物的细胞内吞机制，结果如图11所示。
图11为多肽/雷珠单抗组合物的细胞摄取机制。其中，A和B分别为温度和内吞抑制剂对组合物中多肽和雷珠单抗在HCEC细胞、ARPE-19细胞中摄取的影响。无抑制条件下289WP-FAM或组合物(Mixture)中Cy5-Rani摄取量作为对照(100％)。采用单尾ANOVA分析显著性差异，Dunnett’s检验做校正(样本数3， nsp>0.05,*p<0.05,**p<0.01,***p<0.001)。
结果表明，对于组合物中289WP-FAM的细胞摄取，与对照组相比(289WP-FAM，细胞摄取率为100％)，在HCEC细胞中，4℃或添加抑制剂氯丙嗪、高渗蔗糖、Dynasore(抑制动力蛋白的GTP酶活性)条件下289WP-FAM细胞摄取降幅明显，细胞摄取率分别为23.3％、53.2％、54.4％、49.4％，在ARPE-19中也有类似结果，对应细胞摄取率分别为34.3％、55.8％、70.1％、47.8％，表明在两种细胞中，289WP主要是通过能量依赖、网格蛋白介导的内吞途径进入细胞。而对于雷珠单抗细胞摄取，与对照组相比(Mixture，细胞摄取率为100％)，在 HCEC细胞中，4℃或添加抑制剂氯丙嗪、高渗蔗糖、Dynasore条件下Cy5-Rani细胞摄取率显著下降，细胞摄取率分别为40.6％、37.8％、35.2％、24.4％，在ARPE-19细胞中也有类似结果，对应细胞摄取率分别为79.6％、63.0％、75.7％、31.4％。
实施例10.多肽介导纳米抗体的无创眼内递送
首先，对纳米抗体进行荧光标记。取1mg脱盐纳米抗体(等电点9.6，分子量13kD)溶于600μL碳酸缓冲溶液(10mM，pH9.0)，于4℃预冷，然后滴入异硫氰酸荧光素(FITC)溶液(0.53mg FITC溶于53μL DMSO)，4℃反应24h，反应结束后4℃透析(MWCO 2kD)除去过量FITC及无机盐，冻干得FITC标记纳米抗体。
随后，通过如下方法研究多肽/纳米抗体组合物在小鼠眼内的分布。精密称取FITC标记纳米抗体1.0mg溶于120μL生理盐水，取出60μL与0.5mg穿膜肽89WP混匀，4℃放置24h后使用，作为多肽/纳米抗体组合物，剩余60μL作为游离纳米抗体滴眼液。
小鼠右眼给药，每5min给一次药，共3次，每次给药5μL。其中，游离纳米抗体(Nb)溶液含FITC标记纳米抗体(绿色)浓度为8.33μg/μL，多肽/纳米抗体混合溶液含多肽89WP、FITC标记纳米抗体浓度均为8.33μg/μL。最后一次给药结束后1h处死小鼠，用40mL生理盐水做心脏灌流，摘取眼球，生理盐水冲洗，FAS眼球固定液中固定24h，15％、30％蔗糖溶液梯度脱水，做眼球横截面冰冻切片，采用DAPI染色，在激光共聚焦显微镜下观察荧光信号分布。
滴眼后纳米抗体在各眼组织中分布的半定量分析的结果如下。表6、表7和表8为滴眼给药后纳米抗体在小鼠角膜、角巩膜缘、视网膜部位分布量的比较。
表6为滴眼后纳米抗体的眼角膜分布。游离抗体滴眼组或多肽/纳米抗体溶液滴眼组给药剂量均为125μg荧光标记纳米抗体/眼。采用ImageJ软件计算角膜区域平均绿色荧光强度值(FITC标记的纳米抗体呈绿色荧光)。结果显示，与游离纳米抗体比较，89WP/纳米抗体组合 物滴眼给药，使纳米抗体在角膜部位的分布量增加了3.1倍。
表6滴眼给药后纳米抗体在小鼠眼角膜分布荧光信号强度比较
Figure PCTCN2021112687-appb-000006
*与游离抗体滴眼组相比，平均荧光强度增加的倍数。
表7为滴眼后纳米抗体的角巩膜缘分布。游离抗体滴眼组或多肽/纳米抗体溶液滴眼组给药剂量均为125μg荧光标记纳米抗体/眼。采用ImageJ软件计算角巩膜缘区域平均绿色荧光强度值(FITC标记的纳米抗体呈绿色荧光)。结果显示，与游离纳米抗体比较，89WP/纳米抗体组合物滴眼给药，使纳米抗体在角巩膜缘部位的分布量增加了3.5倍。
表7滴眼给药后纳米抗体在小鼠角-巩膜缘分布荧光信号强度比较
Figure PCTCN2021112687-appb-000007
*与游离抗体滴眼组相比，平均荧光强度增加的倍数。
表8为滴眼后纳米抗体的视网膜分布。游离抗体滴眼组或多肽/纳米抗体溶液滴眼组给药剂量均为125μg荧光标记纳米抗体/眼。采用ImageJ软件计算视网膜区域平均绿色荧光强度值(FITC标记的纳米抗体呈绿色荧光)。结果显示，与游离纳米抗体比较，89WP/纳米抗体组合物滴眼给药，使纳米抗体在视网膜部位的分布量增加了4.1倍。
表8滴眼后纳米抗体小鼠视网膜分布荧光信号强度比较
Figure PCTCN2021112687-appb-000008
*与游离抗体滴眼组相比，平均荧光强度增加的倍数。
上述眼组织的绿色荧光信号半定量分析结果表明，滴眼给药后1h，在角膜、角巩膜缘邻接视网膜、眼底视网膜区域，多肽/纳米抗体溶液 滴眼组绿色荧光信号强度均显著强于游离抗体滴眼组(p<0.01)，表明纳米抗体溶液中加入多肽89WP，可以显著增加滴眼给药后纳米抗体眼内吸收，特别在眼底视网膜分布显著增加。
实施例11.多肽/雷珠单抗组合物滴眼给药后在家兔眼内的分布
首先，制备多肽/雷珠单抗(Rani)溶液。取一定量市售雷珠单抗注射液(10mg/mL)，用市售产品溶剂等体积稀释至5mg/mL，用所得溶液溶解R8至4.0mg/mL得R8/Rani混合溶液，或溶解89WP至7.4mg/mL得89WP/Rani混合溶液，4℃储存备用，使用前至少于4℃孵育24h，并在室温静置1h。
市售雷珠单抗注射液溶剂处方组成：10mM组氨酸盐酸盐，10％α,α-海藻糖，0.01％吐温20，pH5.5。
随后，确定给药及取组织样本方案。
选择1kg左右健康雄性家兔，实验前进行眼科检查确保眼睛正常，实验过程遵循实验动物伦理规范。家兔每只眼滴入30μL药液，含雷珠单抗150μg/眼。给药后1h取组织样本。
取样时，采用安乐死处死家兔，立即由心脏取血1mL左右，加到1.5mL抗凝管中，4℃、2500g离心15min，取上清，-20℃保存备用；分别抽取房水、玻璃体于EP管中，-20℃保存备用；分离视网膜组织，4℃、2500g离心10min，弃上清，10mM PBS洗2次，称重，采用总蛋白提取试剂盒抽提组织总蛋白于10mM PBS中，-20℃保存备用。
基于如下步骤建立ELISA检测方法。
1)抗原包被：用包被液(0.05M碳酸盐缓冲液，pH9.6)将hVEGF-A 165稀释至1μg/mL，将稀释好的抗原包被液于每个酶标板孔中加入100μL，封板后置于4℃包被过夜。
2)洗板：弃去抗原包被液，用洗涤液(0.02M磷酸盐缓冲液，pH7.4，含0.05％吐温20)加满所有包被孔，静置30s后扣干，重复6次。
3)封闭：在酶标板每孔加入250μL封闭液，封板后4℃孵育过夜。
4)弃去封闭液，洗板同上。
5)孵育一抗(含雷珠单抗样品)：取样品各100μL加入酶标孔，封板后37℃孵育1h。
6)弃去一抗溶液，洗板同上。
7)孵育二抗：各孔加入稀释倍数为1:400的HRP标记二抗(F(ab')2-Goat anti-Human IgG(H+L)Cross-Adsorbed Secondary Antibody,HRP)100μL，封板后37℃孵育1h。
8)弃去二抗溶液，洗板同上。
9)显色：每孔加入TMB溶液200μL，封板后37℃避光显色3min，每孔加终止液(2M硫酸溶液)50μL。
10)检测：终止后10min内于酶标仪测定各孔OD 450nm值，以样品浓度为横坐标，以OD 450nm值为纵坐标做标准曲线，据此计算各样品含雷珠单抗浓度。
随后测定雷珠单抗的组织浓度。准备已包被抗原(hVEGF-A165)ELISA板及提取组织(血浆、房水、玻璃体、视网膜总蛋白提取液)，重复上述步骤5)至步骤10)，同时做样品随行检测标曲，计算雷珠单抗组织浓度。
通过ELISA法检测雷珠单抗的组织浓度的结果如下。以样品浓度对应吸光度值做标准曲线。给定浓度范围内(5-120ng/mL)，ELISA检测OD 450nm值与样品浓度线性关系较好(R 2>0.98)，在该浓度范围内，采用ELISA法检测雷珠单抗浓度方法可行。
雷珠单抗在眼组织中的分布如下。滴眼给药后1h，兔眼各组织雷珠单抗浓度如图12所示。
图12为滴眼给药1h后兔体内各组织(血浆、房水、玻璃体、视网膜)雷珠单抗浓度。阴影区域为文献报道的雷珠单抗半数有效浓度(EC 50)。采用单尾ANOVA分析显著性差异，Tukey’s检验做校正( nsp>0.05,*p<0.05,**p<0.01，与Rani组相比)。
结果表明，对于游离雷珠单抗滴眼组(Rani)，给药后1h，兔眼 房水、玻璃体、视网膜药物浓度几乎测不出，远低于文献报道的雷珠单抗半数有效浓度(EC 50)；对于R8/Rani溶液组，经滴眼给药，在房水中未达到有效治疗浓度，在玻璃体达到有效治疗浓度下限，在视网膜组织浓度可达到有效治疗浓度，优于游离雷珠单抗组(p＝0.0377)；对于89W/Rani复合物组，经滴眼给药，在房水未达到有效治疗浓度，在玻璃体和视网膜组织可达到有效治疗浓度，显著优于游离雷珠单抗组(p＝0.0025)。
实施例12.多肽/雷珠单抗组合物滴眼给药后在家兔体内的药动学
首先，制备滴眼液。制备多肽/雷珠单抗组合物，取一定量市售雷珠单抗注射剂(10mg/mL)，用市售产品溶剂等体积稀释至5mg/mL，用所得溶液溶解29WP至2.48mg/mL得组合物29WP/Rani，或溶解289WP至2.54mg/mL得组合物289WP/Rani，4℃储存备用，使用前至少于4℃孵育24h，并在室温静置1h。
随后，确定给药及取样方案。选择1kg左右健康雄性家兔，实验前进行眼科检查确保眼睛正常，实验过程遵循实验动物伦理规范。家兔每只眼滴入30μL不同组合物溶液，含雷珠单抗150μg/眼。给药后1h、4h、8h、12h、24h分别取眼组织样品。
接着，测定雷珠单抗的组织浓度。准备已包被抗原(hVEGF-A165)ELISA板及提取组织(血浆、房水、玻璃体、视网膜总蛋白提取液)，重复实施例11中的建立ELISA检测方法中的步骤5)至步骤10)，同时做样品随行检测标曲，计算雷珠单抗组织浓度。
结果如下：给定浓度范围内(5-120ng/mL)，ELISA检测OD 450nm值与雷珠单抗样品浓度线性关系较好(R 2>0.98)，在该浓度范围内，采用ELISA法检测雷珠单抗浓度方法可行。
多肽/雷珠单抗组合物滴眼后兔体内药动学行为。采用ELISA法检测滴眼给药后多肽介导雷珠单抗在兔体内各组织分布，结果如图13、 表9所示。
图13为滴眼给药后多肽/雷珠单抗组合物在兔体内的浓度分布变化。其中，给药剂量：289WP/Rani组合物组含289WP 76.2μg/眼、雷珠单抗150μg/眼；29WP/Rani组合物组含29WP 74.4μg/眼、雷珠单抗150μg/眼；Rani组含雷珠单抗150μg/眼。检测给药后1h、4h、8h、12h、24h雷珠单抗组织浓度。阴影区域为文献报道的雷珠单抗半数有效浓度(EC 50)。采用单尾ANOVA分析显著性差异，Tukey’s检验做校正( nsp>0.05,*p<0.05,**p<0.01，与Rani组相比)。
表9滴眼给药后多肽介导雷珠单抗兔体内浓度分布(ng/mL or ng/g)。
Figure PCTCN2021112687-appb-000009
结果表明，药物经眼表滴入后可能存在全身吸收，以血浆中雷珠单抗浓度表征雷珠单抗全身分布行为，给药后1h，289WP/Rani组合物组雷珠单抗血浆浓度为17.2±1.4ng/mL，29WP/Rani组合物组为21.7±9.2ng/mL，达到文献报道的雷珠单抗半数有效浓度(EC 50)，而Rani组滴眼给药1h后在血液中未检出雷珠单抗，给药后4h，289WP/Rani组合物组及29WP/Rani组合物组血浆浓度降至0.9±0.9ng/mL、14.0±5.0ng/mL，给药后8h，各组雷珠单抗血浆浓度基本为0，表明滴眼给药后，多肽介导雷珠单抗存在一定全身吸收，但给药后4h雷珠单抗血浆浓度大幅下降，8h后基本清除完毕。对于房水中雷珠单抗含量，给药后1h和4h，289WP/Rani组合物组及29WP/Rani组合物组雷珠单抗浓度处于文献报道的雷珠单抗半数有效浓度(EC 50)范围内(9.0-28.8ng/mL)，前者略高，而Rani组给药后1h房水中雷珠单抗浓度仅为 1.7ng/mL，表明雷珠单抗单独滴眼后难以在房水中达到有效治疗浓度。对于玻璃体内雷珠单抗浓度，仅289WP/Rani组合物组滴眼后1h可达到文献报道的雷珠单抗半数有效浓度(EC 50)(27.0±7.8ng/mL)。以视网膜中雷珠单抗浓度表征抗体向病灶部位分布，给药后1h、4h及8h，289WP/Rani组合物组雷珠单抗视网膜浓度分别为107.1±55.4ng/g、63.4±43.6ng/g、21.9±4.4ng/g，均值分别为游离抗体组的20.6、12.2、4.2倍(p<0.05)，并且高于或处于文献报道的雷珠单抗半数有效浓度(EC 50)浓度范围内，表明单次滴眼给药后8h内，289WP/Rani组合物可维持视网膜中的雷珠单抗处于有效浓度范围内，而29WP/Rani组合物滴眼给药后1-8h，视网膜浓度在13.7-35.8ng/g，也可达到文献报道的雷珠单抗半数有效浓度(EC 50)，但浓度偏低，持续时间较短，表明29WP眼内递送雷珠单抗效果不如289WP。同时考虑到多肽/雷珠单抗组合物滴眼给药后，雷珠单抗视网膜浓度>玻璃体或房水中浓度，因此推断多肽介导雷珠单抗到达视网膜可能是通过结膜→巩膜→脉络膜→视网膜途径吸收。
实施例13.多肽/阿柏西普组合物滴眼给药后在家兔体内的药动学
首先，制备滴眼液。制备多肽/阿柏西普组合物，采用市售阿柏西普注射液溶剂稀释阿柏西普(40mg/mL)至20mg/mL，取此溶液溶解多肽289WP至6.16mg/mL，4℃储存备用，使用前至少于4℃孵育24h，并在室温静置1h。
市售阿柏西普注射液溶剂处方组成：10mM磷酸盐缓冲溶液，40mM氯化钠，0.03％吐温20，5％蔗糖，pH6.2。
其次，确定给药及取样方案。选择1kg左右健康雄性家兔，实验前进行眼科检查确保眼睛正常，实验过程遵循实验动物伦理规范。家兔每只眼滴入30μL不同组合物溶液，含阿柏西普600μg/眼。给药后1h取眼组织样品。
随后，测定阿柏西普组织浓度。准备已包被抗原(hVEGF-A165) ELISA板及提取组织(血浆、房水、玻璃体、视网膜总蛋白提取液)，重复实施例11中的建立ELISA检测方法中的步骤5)至步骤10)，同时做样品随行检测标曲，计算阿柏西普组织浓度。
结果如下：给定浓度范围内(0-156.25ng/mL)，ELISA检测OD 450 nm值与阿柏西普样品浓度线性关系较好(R 2>0.98)，在该浓度范围内，采用ELISA法检测阿柏西普浓度方法可行。
采用ELISA法检测滴眼给药后多肽介导阿柏西普在兔体内各组织分布，结果如图14所示。
图14为滴眼给药后多肽/阿柏西普溶液在兔体内的浓度分布。其中，给药剂量：Afli组含阿柏西普600μg/眼；289WP/Afli组合物组含289WP 184.8μg/眼、阿柏西普600μg/眼。检测给药后1h阿柏西普组织浓度。采用双尾非配对t检验分析显著性差异( nsp>0.05,*p<0.05)。
结果表明，给药后1h，游离阿柏西普组或289WP/Afli组合物组血浆中均未检出阿柏西普。与Afli组相比，289WP/Afli组合物滴眼后房水(p<0.05)、玻璃体中阿柏西普浓度略高，而视网膜浓度达到237.6±162.2ng/g，显著高于Afli组(p<0.05)，表明多肽289WP可显著改善阿柏西普的眼部吸收。与多肽/雷珠单抗滴眼液类似，阿柏西普可能经结膜→巩膜→脉络膜→视网膜途径吸收。
上述实验证明，与仅使用所述生理pH条件下带正电荷的药物的情况比较，所述组合物使得细胞摄取显著增加。通过本发明的组合物，能够介导所述生理pH条件下带正电荷的药物高效地透过眼部的吸收屏障，促进药物进入眼内并到达眼后段，进而提高生理pH条件下带正电荷的药物的眼部生物利用度，显著促进了生理pH条件下带正电荷的药物的细胞摄取。

Claims (19)

  1. 一种用于治疗眼部疾病的组合物，该组合物包括：
    (i)生理pH条件下带正电荷的药物，和
    (ii)野生型穿膜肽penetratin的衍生物，所述野生型穿膜肽penetratin的衍生物具有下述氨基酸序列：
    RX 1IKIWFX 2X 3RRMKWKK
    其中，X 1、X 2和X 3代表疏水性氨基酸，选自天然来源的氨基酸丙氨酸(alanine，A)、缬氨酸(valine，V)、亮氨酸(leucine，L)、异亮氨酸(isoleucine，I)、脯氨酸(proline，P)、苯丙氨酸(phenylalanine，F)、色氨酸(tryptophan，W)、甲硫氨酸(methionine，M)和非天然来源的氨基酸α-氨基丁酸(α-aminobutyric acid)、α-氨基戊酸(α-aminopentanoic acid)、α-氨基己酸(α-aminohexanoic acid)、α-氨基庚酸(α-aminoheptanoic acid)，以及它们的组合。
  2. 根据权利要求1所述的用于治疗眼部疾病的组合物，其中所述组合物是溶液或混悬液。
  3. 根据权利要求1所述的用于治疗眼部疾病的组合物，其特征在于，其中，X 1、X 2和X 3代表疏水性氨基酸，X 1、X 2和X 3中的至少两个选自天然来源的氨基酸丙氨酸(alanine，A)、缬氨酸(valine，V)、亮氨酸(leucine，L)、异亮氨酸(isoleucine，I)、脯氨酸(proline，P)、苯丙氨酸(phenylalanine，F)、色氨酸(tryptophan，W)、甲硫氨酸(methionine，M)和非天然来源的氨基酸α-氨基丁酸(α-aminobutyric acid)、α-氨基戊酸(α-aminopentanoic acid)、α-氨基己酸(α-aminohexanoic acid)、α-氨基庚酸(α-aminoheptanoic acid)，以及它们的组合。
  4. 根据权利要求1用于治疗眼部疾病的组合物，其特征在于， X 1、X 2或X 3为色氨酸(tryptophan，W)。
  5. 根据权利要求1用于治疗眼部疾病的组合物，其特征在于，X 1、X 2或X 3中的至少两个为色氨酸(tryptophan，W)。
  6. 根据权利要求1用于治疗眼部疾病的组合物，其特征在于，所述野生型穿膜肽penetratin的衍生物的氨基酸序列为：
    RWIKIWFQNRRMKWKK
    RQIKIWFWNRRMKWKK
    RQIKIWFQWRRMKWKK
    RWIKIWFWNRRMKWKK
    RWIKIWFQWRRMKWKK
    RQIKIWFWWRRMKWKK
    RWIKIWFWWRRMKWKK。
  7. 根据权利要求1用于治疗眼部疾病的组合物，其特征在于，所述野生型穿膜肽penetratin的衍生物的氨基酸序列为：
    RWIKIWFWNRRMKWKKK
    RWIKIWFQWRRMKWKKK
    RQIKIWFWWRRMKWKKK
    RWIKIWFWWRRMKWKK。
  8. 根据权利要求1所述的用于治疗眼部疾病的组合物，其中所述药物为多肽或蛋白类药物。
  9. 根据权利要求1所述的用于治疗眼部疾病的组合物，其中所述药物选自以下的一种或多种：纳米抗体(Nanobody)、雷珠单抗 (Ranibizumab)、阿柏西普(Aflibercept)、奥克纤溶酶(Ocriplasmin)、贝伐单抗(Bevacizumab)、阿达木单抗(Adalimumab)、阿特珠单抗(Atezolizumab)、贝利木单抗(Belimumab)、西妥昔单抗(Cetuximab)、达洛珠单抗(Dalotuzumab)、地诺单抗(Denosumab)、埃罗妥珠单抗(Elotuzumab)、英夫利昔单抗(Infliximab)、伊匹单抗(Ipilimumab)、伊奇珠单抗(Ixekizumab)、那他珠单抗(Natalizumab)、NIST单抗(NISTmab)、纳武单抗(Nivolumab)、奥滨尤妥珠单抗(Obinutuzumab)、奥法木单抗(Ofatumumab)、帕利珠单抗(Palivizumab)、派姆单抗(Pembrolizumab)、帕妥珠单抗(Pertuzumab)、雷莫芦单抗(Ramucirumab)、利妥昔单抗(Rituximab)、曲妥珠单抗(Trastuzumab)和内皮抑素(Endostatin)。
  10. 根据权利要求1所述的用于治疗眼部疾病的组合物，其中所述药物选自以下的一种或多种：纳米抗体、雷珠单抗、阿柏西普、奥克纤溶酶、贝伐单抗和西妥昔单抗。
  11. 根据权利要求1所述的用于治疗眼部疾病的组合物，其中所述药物选自以下的一种或多种：雷珠单抗、阿柏西普和贝伐单抗。
  12. 根据权利要求9所述的用于治疗眼部疾病的组合物，其中所述纳米抗体选自以下的一种或多种：卡帕珠单抗(Caplacizumab)、奥索拉珠单抗(Ozoralizumab)和伏巴利珠单抗(Vobarilizumab)。
  13. 根据权利要求1所述的用于治疗眼部疾病的组合物，其中野生型穿膜肽penetratin的衍生物与所述药物的比例为摩尔比为0.1:1-50:1。
  14. 根据权利要求1所述的用于治疗眼部疾病的组合物，其中野生型穿膜肽penetratin的衍生物与所述药物的比例为摩尔比为0.5:1-35:1。
  15. 根据权利要求1所述的用于治疗眼部疾病的组合物，其中野生型穿膜肽penetratin的衍生物与所述药物的比例为摩尔比为1:1-20:1。
  16. 根据权利要求1所述的用于治疗眼部疾病的组合物，其中野生型穿膜肽penetratin的衍生物与所述药物的比例为摩尔比为3:1-15:1。
  17. 一种为需要的受试者治疗眼部疾病的方法，所述方法包括施用治疗有效量的根据权利要求1-16中任一项所述的用于治疗眼部疾病的组合物。
  18. 根据权利要求2所述的方法，其中所述方法包括将治疗有效量的根据权利要求1-16中任一项所述的组合物给患者滴眼给药。
  19. 根据权利要求1-16中任一项所述的组合物在制备用于治疗眼部疾病的药物中的用途。
PCT/CN2021/112687 2020-08-17 2021-08-16 药物和野生型穿膜肽衍生物的组合物 WO2022037514A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US18/021,868 US20230357334A1 (en) 2020-08-17 2021-08-16 Composition of drug and wild-type cell-penetrating peptide derivative
CA3192067A CA3192067A1 (en) 2020-08-17 2021-08-16 Composition of drug and wild-type cell-penetrating peptide derivative
JP2023512007A JP2023539460A (ja) 2020-08-17 2021-08-16 薬剤と野生型膜透過ペプチド誘導体の組成物
EP21857609.8A EP4197558A1 (en) 2020-08-17 2021-08-16 Composition of drug and wild-type cell-penetrating peptide derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010825480.0 2020-08-17
CN202010825480.0A CN114073774A (zh) 2020-08-17 2020-08-17 药物和野生型穿膜肽衍生物的组合物

Publications (1)

Publication Number Publication Date
WO2022037514A1 true WO2022037514A1 (zh) 2022-02-24

Family

ID=80281153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/112687 WO2022037514A1 (zh) 2020-08-17 2021-08-16 药物和野生型穿膜肽衍生物的组合物

Country Status (7)

Country Link
US (1) US20230357334A1 (zh)
EP (1) EP4197558A1 (zh)
JP (1) JP2023539460A (zh)
CN (1) CN114073774A (zh)
CA (1) CA3192067A1 (zh)
TW (1) TW202227137A (zh)
WO (1) WO2022037514A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270974B (zh) * 2023-03-09 2024-03-12 湖南大学 一种组合物、阿柏西普递送系统和制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107638405A (zh) * 2016-07-15 2018-01-30 复旦大学 一种眼内递药组合物及其制备方法
CN108976288A (zh) 2017-06-05 2018-12-11 复旦大学 基于野生型穿膜肽penetratin的亲脂性衍生物
WO2019018350A1 (en) * 2017-07-17 2019-01-24 Keith Roizman TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
CN109420178A (zh) * 2017-09-04 2019-03-05 复旦大学 多价穿膜肽类生物大分子递送载体及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107638405A (zh) * 2016-07-15 2018-01-30 复旦大学 一种眼内递药组合物及其制备方法
CN108976288A (zh) 2017-06-05 2018-12-11 复旦大学 基于野生型穿膜肽penetratin的亲脂性衍生物
WO2019018350A1 (en) * 2017-07-17 2019-01-24 Keith Roizman TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
CN109420178A (zh) * 2017-09-04 2019-03-05 复旦大学 多价穿膜肽类生物大分子递送载体及其应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
HOPKINS ESHARMA S: "StatPearls [Internet", 16 June 2019, STATPEARLS PUBLISHING, article "Physiology, Acid Base Balance"
INVEST OPHTHALMOL VIS SCI, vol. 58, no. 5, 2017, pages 2578 - 2590
J CONTROL RELEASE, vol. 118, no. 2, 2007, pages 177 - 84
J. CONTROLLED RELEASE, vol. 309, 2019, pages 106 - 124
JOVCEVSKA IMUYLDERMANS S: "The Therapeutic Potential of Nanobodies", BIODRUGS, vol. 34, 2020, pages 11 - 26, XP055872374, DOI: 10.1007/s40259-019-00392-z
KENTARO TOMII: "Encyclopedia of Bioinformatics and Computational Biology", vol. 2, 2019, article "Protein Properties", pages: 28 - 33
MELVIN E. LASKINEIL A. KURTZMAN: "Acid-base disorders in medicine", DISEASE-A-MONTH, vol. 42, no. 2, 1996, pages 59 - 125, XP027522599
RUBEL CHAKRAVARTYSHREYA GOELWEIBO CAI: "Nanoantibody: The ''Magic Bullet'' for Molecular Imaging?", THERANOSTICS, vol. 4, no. 4, 2014, pages 386 - 398

Also Published As

Publication number Publication date
CA3192067A1 (en) 2022-02-24
TW202227137A (zh) 2022-07-16
CN114073774A (zh) 2022-02-22
EP4197558A1 (en) 2023-06-21
US20230357334A1 (en) 2023-11-09
JP2023539460A (ja) 2023-09-14

Similar Documents

Publication Publication Date Title
De Cogan et al. Topical delivery of anti-VEGF drugs to the ocular posterior segment using cell-penetrating peptides
US11738064B2 (en) Pharmaceutical composition for preventing and treating eye diseases, containing as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
US20220008546A1 (en) Polypeptide-based ocular absorption enhancer and application thereof
TW201642838A (zh) 脂質體調配物
WO2022037514A1 (zh) 药物和野生型穿膜肽衍生物的组合物
EP3672641B1 (en) Composition comprising vegf antagonists and a cationic peptide and uses thereof
CN117467025B (zh) 一种抗vegf和补体双功能融合蛋白及其应用
ES2791251T3 (es) Péptidos de Ledgf y formulaciones de los mismos para el tratamiento de trastornos degenerativos
US20230054032A1 (en) Compositions and methods for treating ocular disease
CN111315771B (zh) 针对mfap4的抗体
RU2669787C2 (ru) Средство для лечения заболевания, сопровождающегося отеком макулы вследствие повышенной экспрессии VEGF-A
EP4260871A1 (en) Optical nerve protecting agent containing anti-lrp1 antibody
WO2023083243A1 (zh) 一种抗il-17/vegf双功能融合蛋白及其用途
US20240052005A1 (en) Improved cell-penetrating peptides and fusion proteins
JP2021138629A (ja) 薬物デリバリーキャリアおよびこれを用いる医薬組成物
CN111201247A (zh) 治疗方法和新颖构建体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21857609

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023512007

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3192067

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2021857609

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021857609

Country of ref document: EP

Effective date: 20230317